

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Strategies for developing and optimizing cancer... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-654/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-654" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Strategies for developing and optimizing cancer vaccines" />
    
            <meta name="og:title" content="F1000Research Article: Strategies for developing and optimizing cancer vaccines.">
            <meta name="og:description" content="Read the latest article version by Hoyoung M. Maeng, Jay A. Berzofsky, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="20468">
            <meta name="article-id" content="18693">
            <meta name="dc.title" content="Strategies for developing and optimizing cancer vaccines">
            <meta name="dc.description" content="With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint inhibitors, strategies to improve the response rate and duration of current cancer immunotherapeutics are highly sought. In that sense, investigators around the globe have been putting spurs on the development of effective cancer vaccines in humans after decades of efforts that led to limited clinical success. In more than three decades of research in pursuit of targeted and personalized immunotherapy, several platforms have been incorporated into the list of cancer vaccines from live viral or bacterial agents harboring antigens to synthetic peptides with the hope of stronger and durable immune responses that will tackle cancers better. Unlike adoptive cell therapy, cancer vaccines can take advantage of using a patient&rsquo;s entire immune system that can include more than engineered receptors or ligands in developing antigen-specific responses. Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting.">
            <meta name="dc.subject" content="cancer vaccine, tumor antigen, immunotherapy">
            <meta name="dc.creator" content="Maeng, Hoyoung M.">
            <meta name="dc.creator" content="Berzofsky, Jay A.">
            <meta name="dc.date" content="2019/05/13">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.18693.1">
            <meta name="dc.source" content="F1000Research 2019 8:654">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="cancer vaccine">
            <meta name="prism.keyword" content="tumor antigen">
            <meta name="prism.keyword" content="immunotherapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/05/13">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="654">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.18693.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-654">
            <meta name="citation_title" content="Strategies for developing and optimizing cancer vaccines">
            <meta name="citation_abstract" content="With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint inhibitors, strategies to improve the response rate and duration of current cancer immunotherapeutics are highly sought. In that sense, investigators around the globe have been putting spurs on the development of effective cancer vaccines in humans after decades of efforts that led to limited clinical success. In more than three decades of research in pursuit of targeted and personalized immunotherapy, several platforms have been incorporated into the list of cancer vaccines from live viral or bacterial agents harboring antigens to synthetic peptides with the hope of stronger and durable immune responses that will tackle cancers better. Unlike adoptive cell therapy, cancer vaccines can take advantage of using a patient&rsquo;s entire immune system that can include more than engineered receptors or ligands in developing antigen-specific responses. Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting.">
            <meta name="citation_description" content="With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint inhibitors, strategies to improve the response rate and duration of current cancer immunotherapeutics are highly sought. In that sense, investigators around the globe have been putting spurs on the development of effective cancer vaccines in humans after decades of efforts that led to limited clinical success. In more than three decades of research in pursuit of targeted and personalized immunotherapy, several platforms have been incorporated into the list of cancer vaccines from live viral or bacterial agents harboring antigens to synthetic peptides with the hope of stronger and durable immune responses that will tackle cancers better. Unlike adoptive cell therapy, cancer vaccines can take advantage of using a patient&rsquo;s entire immune system that can include more than engineered receptors or ligands in developing antigen-specific responses. Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting.">
            <meta name="citation_keywords" content="cancer vaccine, tumor antigen, immunotherapy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Hoyoung M. Maeng">
            <meta name="citation_author_institution" content="Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA">
            <meta name="citation_author" content="Jay A. Berzofsky">
            <meta name="citation_author_institution" content="Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA">
            <meta name="citation_publication_date" content="2019/05/13">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="654">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.18693.1">
            <meta name="citation_firstpage" content="654">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-654/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-654.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=20468 /> <input type=hidden id=articleId name=articleId value=18693 /> <input type=hidden id=xmlUrl value="/articles/8-654/v1/xml"/> <input type=hidden id=xmlFileName value="-8-654-v1.xml"> <input type=hidden id=article_uuid value=524009f8-be9a-431f-bad9-2a142f31ff5e /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Strategies for developing and optimizing cancer vaccines"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.18693.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.18693.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-654"
  },
  "headline": "Strategies for developing and optimizing cancer vaccines",
  "datePublished": "2019-05-13T16:11:25",
  "dateModified": "2019-05-13T16:11:25",
  "author": [
    {
      "@type": "Person",
      "name": "Hoyoung M. Maeng"
    },    {
      "@type": "Person",
      "name": "Jay A. Berzofsky"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint inhibitors, strategies to improve the response rate and duration of current cancer immunotherapeutics are highly sought. In that sense, investigators around the globe have been putting spurs on the development of effective cancer vaccines in humans after decades of efforts that led to limited clinical success. In more than three decades of research in pursuit of targeted and personalized immunotherapy, several platforms have been incorporated into the list of cancer vaccines from live viral or bacterial agents harboring antigens to synthetic peptides with the hope of stronger and durable immune responses that will tackle cancers better. Unlike adoptive cell therapy, cancer vaccines can take advantage of using a patient&rsquo;s entire immune system that can include more than engineered receptors or ligands in developing antigen-specific responses. Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-654/v1",
            "name": "Strategies for developing and optimizing cancer vaccines"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Strategies for developing and optimizing cancer vaccines </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=20468 data-id=18693 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18693.1" data-recommended="" data-doi="10.12688/f1000research.18693.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-654/v1/pdf?article_uuid=524009f8-be9a-431f-bad9-2a142f31ff5e" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-18693-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-18693-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-18693-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Maeng HM and Berzofsky JA. Strategies for developing and optimizing cancer vaccines [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):654 (<a class=new-orange href="https://doi.org/10.12688/f1000research.18693.1" target=_blank>https://doi.org/10.12688/f1000research.18693.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-18693-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=18693 id=track-article-signin-18693 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18693?target=/articles/8-654/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20468 /> <input name=articleId type=hidden value=18693 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Strategies for developing and optimizing cancer vaccines</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Hoyoung M. Maeng<a href="https://orcid.org/0000-0002-8194-6089" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8194-6089</div>,&nbsp;</span><span class=""><a href="mailto:berzofsj@mail.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jay A. Berzofsky</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Hoyoung M. Maeng<a href="http://orcid.org/0000-0002-8194-6089" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-8194-6089</div>,&nbsp;</span><span class=""><a href="mailto:berzofsj@mail.nih.gov" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jay A. Berzofsky</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 13 May 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.18693.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA<br/> <p> <div class=margin-bottom> Hoyoung M. Maeng <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Jay A. Berzofsky <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=50347-47956></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=50349-47957></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> With the spotlight on cancer immunotherapy and the expanding use of immune checkpoint inhibitors, strategies to improve the response rate and duration of current cancer immunotherapeutics are highly sought. In that sense, investigators around the globe have been putting spurs on the development of effective cancer vaccines in humans after decades of efforts that led to limited clinical success. In more than three decades of research in pursuit of targeted and personalized immunotherapy, several platforms have been incorporated into the list of cancer vaccines from live viral or bacterial agents harboring antigens to synthetic peptides with the hope of stronger and durable immune responses that will tackle cancers better. Unlike adoptive cell therapy, cancer vaccines can take advantage of using a patient’s entire immune system that can include more than engineered receptors or ligands in developing antigen-specific responses. Advances in molecular technology also secured the use of genetically modified genes or proteins of interest to enhance the chance of stronger immune responses. The formulation of vaccines to increase chances of immune recognition such as nanoparticles for peptide delivery is another area of great interest. Studies indicate that cancer vaccines alone may elicit tumor-specific cellular or humoral responses in immunologic assays and even regression or shrinkage of the cancer in select trials, but novel strategies, especially in combination with other cancer therapies, are under study and are likely to be critical to achieve and optimize reliable objective responses and survival benefit. In this review, cancer vaccine platforms with different approaches to deliver tumor antigens and boost immunity are discussed with the intention of summarizing what we know and what we need to improve in the clinical trial setting. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> cancer vaccine, tumor antigen, immunotherapy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Jay A. Berzofsky (<a href="mailto:berzofsj@mail.nih.gov">berzofsj@mail.nih.gov</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Jay A. Berzofsky </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This work was supported by the National Cancer Institute. <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Maeng HM and Berzofsky JA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Maeng HM and Berzofsky JA. Strategies for developing and optimizing cancer vaccines [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):654 (<a href="https://doi.org/10.12688/f1000research.18693.1" target=_blank>https://doi.org/10.12688/f1000research.18693.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 13 May 2019, <b>8</b>(F1000 Faculty Rev):654 (<a href="https://doi.org/10.12688/f1000research.18693.1" target=_blank>https://doi.org/10.12688/f1000research.18693.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 13 May 2019, <b>8</b>(F1000 Faculty Rev):654 (<a href="https://doi.org/10.12688/f1000research.18693.1" target=_blank>https://doi.org/10.12688/f1000research.18693.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e159>Introduction</h2><p class="" id=d77711e162>Cancer vaccines have been extensively researched in both animal models and humans over the past 30 years across many different types of cancer. With continued attempts to develop effective cancer vaccines, several agents are licensed or were granted Orphan Drug Designation. However, the limitation in demonstrating clinical response has led to US Food and Drug Administration (FDA) approval of only one agent, sipuleucel-T, a cancer vaccine that is used to treat metastatic castration-resistant prostatic cancer in a limited group of nearly asymptomatic patients, indicating an apparent unmet need<sup><a href="#ref-1">1</a></sup>.</p><p class="" id=d77711e169>Cancer vaccines are highlighted in the era of cancer immunotherapy as they can induce immune responses in “cold” tumors that do not appear immunogenic on their own, potentially converting them to “hot” tumors amenable to checkpoint blockade therapy. Hot tumors are defined as ones in which the tumor itself has induced an immune response of infiltrating T cells that are not able to function because of various checkpoints such as PD-1, CTLA-4, LAG3, TIM3, TIGIT, or other immunoregulatory mechanisms involving regulatory cells (regulatory T cells, myeloid-derived suppressor cells (MDSCs), M2 macrophages, regulatory natural killer (NK) T cells, and so on) or regulatory cytokines (transforming growth factor-beta [TGFβ]), interleukin-10 (IL-10), and IL-13)<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. A cold tumor is one that is not sufficiently immunogenic to induce such infiltrating T cells on its own, or has excluded these cells. Without a T-cell response, checkpoint blockade has no immune response to augment. Cancer vaccines can fill this gap by inducing T-cell immunity that then can be made more effective by overcoming the inhibitory signals through checkpoint blockade<sup><a href="#ref-4">4</a>–<a href="#ref-9">9</a></sup> or other methods to overcome other immunosuppressive mechanisms. For example, blockade of TGFβ has been found to complement the effect of PD-1 blockade in enhancing cancer vaccine efficacy<sup><a href="#ref-10">10</a></sup>, perhaps because it allows entry of T cells into the tumor<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>. Anti-TGFβ proved safe in a phase I clinical trial and even showed some evidence of clinical activity in patients with melanoma<sup><a href="#ref-13">13</a></sup>, so it could be combined with anti-PD-1. Thus, understanding the difference between the cancer vaccine platforms is crucial in maximizing the synergistic effect with other immunotherapeutics and anti-cancer therapies.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e204>Shared tumor antigens versus neoantigens</h2><p class="" id=d77711e207>For most of their history, cancer vaccines have focused on “shared” tumor antigens, meaning antigens that are common to most cancers of a given histological type<sup><a href="#ref-14">14</a>,<a href="#ref-15">15</a></sup>. A decade ago, a working group was assembled to develop a list of the highest-priority shared tumor antigens<sup><a href="#ref-16">16</a></sup>. These include antigens like hypoglycosylated MUC1, Wnt1, HER2, MART1, gp100, and tyrosinase. Many of these have shown promising early results but none has been licensed yet as a vaccine. For example, hypoglycosylated MUC1 was found to be a tumor antigen common to many adenocarcinomas<sup><a href="#ref-17">17</a></sup>, and clinical trials have shown promise<sup><a href="#ref-18">18</a></sup>. HER2 is known to be a surface antigen that is also a driver oncogene product constitutively signaling the cell to divide. Monoclonal antibody therapy against HER2 is a mainstay of treatment for HER2<sup>+</sup> breast cancer and some other HER2-expressing cancers, but no vaccine that induces such antibodies is clinically available. However, peptide vaccines targeting HER2 have been successful in inducing immunity in patients with breast and ovarian cancer<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>. An ongoing trial of a dendritic cell (DC) vaccine transduced with an adenovirus expressing the extracellular and transmembrane domains of HER2, which cures mice of HER2<sup>+</sup> tumors by inducing antibodies, is resulting in some complete and partial responses and stable disease in close to 50% of vaccinated patients with advanced metastatic HER2-expressing cancers who have failed standard therapies (Maeng <i>et al</i>., manuscript in preparation). Another shared antigen, TARP<sup><a href="#ref-21">21</a></sup>, expressed in about 95% of prostate cancers of all Gleason types and about 50% of breast cancers, has shown promise as a peptide vaccine in HLA-A*0201<sup>+</sup> patients with stage D0 prostate cancer by reducing the tumor growth rate as measured by prostate-specific antigen (PSA) slope in about 74% of vaccinated patients at 1 year<sup><a href="#ref-22">22</a></sup>.</p><p class="" id=d77711e257>In the past 5 years or so, neoantigens have been found to represent a substantial portion of tumor antigens. These are antigens that are created by point mutations, insertions, deletions, or translocations that produce novel amino acid sequences present only in the tumor and not normal cells. Some fraction of these can be presented by HLA molecules of the patient and thus constitute neoepitopes of neoantigens. It was found that the response rate to checkpoint inhibitors correlated with the number of such mutations (tumor mutational burden) or predicted neoepitopes<sup><a href="#ref-4">4</a></sup>. For this reason, multiple groups are developing strategies to identify such neoepitopes in each patient’s cancer and then synthesize a personalized vaccine to treat his or her cancer<sup><a href="#ref-23">23</a></sup>. One of the first attempts at making a neoepitope vaccine, before the term was coined, was the targeting of mutant epitopes created by point mutations in Kras or p53 that commonly occur in cancers. In a vaccine trial of such personalized mutant ras and p53 peptides, the cancer patients who made an interferon-gamma (IFNγ) T-cell response to their own mutant peptide vaccine had a median overall survival more than a year longer than patients who did not make such a T-cell response<sup><a href="#ref-24">24</a></sup>. Now that the technology to rapidly identify such mutations has matured, more such approaches are under way. It should also be noted that not all neoantigens are of equal quality for the induction of anti-tumor immunity; variation in quality depends on factors such as affinity for the patient’s HLA molecules, frequency of relevant T-cell receptors (TCRs) in the repertoire (which may be affected by cross-reactivity with microbial antigens), and expression levels in the tumor<sup><a href="#ref-25">25</a>–<a href="#ref-28">28</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e282>Vaccine platform types</h2><p class="" id=d77711e285>Developing preclinical models for cancer vaccines has been difficult as immune systems of animals and humans are different; more importantly, mouse tumor models do not often mimic the human disease that presents clinically when already established. Despite the challenges, each translation of cancer vaccines to the clinical setting has yielded a deeper understanding of each platform. In this article, we will focus on those with successful translation to clinical trials, reviewing the historical changes to develop vaccines that are more effective.</p><p class="" id=d77711e288>Cancer vaccines can be categorized in a few different ways. One way to classify cancer vaccines is based on the biologic formulation or antigen source of the vaccine: nucleic acids, peptides, recombinant proteins, microbial vectors, whole tumor cells either autologous or allogeneic, manipulated antigen-presenting cells (APCs), and other artificial systems (<a href="#f1">Figure 1</a>). The other major way is based on the type of cancer antigens, the methods of antigen selection, or uniqueness of the antigen (for example, shared versus neoepitopes). There have been controversies about whether an oncolytic virus should be considered a cancer vaccine or not. Strictly speaking, oncolytic viruses that are intended to induce direct cytopathic effects as the main mechanism of action are different from cancer vaccines, even though some of the post-treatment immune reactions might initiate similar immunologic cascades, turning the tumor cells into “endogenous vaccines”<sup><a href="#ref-29">29</a></sup>. The route and mode of delivery are also important topics but should be addressed in the context of an individual vaccine formulation to understand why certain routes may or may not work better for a particular vaccine or formulation.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/20468/6bd80b6d-0d6c-4fdc-b7f6-2705b787adfe_figure1.gif"><img alt="6bd80b6d-0d6c-4fdc-b7f6-2705b787adfe_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/20468/6bd80b6d-0d6c-4fdc-b7f6-2705b787adfe_figure1.gif"></a><div class=caption><h3>Figure 1. Cancer vaccine platforms and interactions in the immune system.</h3><p id=d77711e308>Antigen-specific cancer vaccines come in a variety of compositions to deliver the tumor antigen of interest. Compared with cell-based vaccines, the rest of the platforms have the merit of potential for simpler manufacturing and flexibility in delivery of the vaccines along with special features of individual platforms. Cell-based vaccines, as represented by dendritic cell (DC) vaccines, have an advantage in that investigators can perform targeted loading of the antigen of interest, circumvent poor DC maturation in patients with cancer, and manipulate <i>in vivo</i>, but standardizing the manufacturing and quality assessment is another hurdle to surmount. As the network of the immune system is unveiled further, more efficient and intelligent design of cancer vaccine platforms will expand the territory to use these either by themselves or in combination with other cancer therapy options in this era in which cancer immunotherapy has become the fourth pillar in oncology, beyond surgery, chemotherapy, and radiation. IFN, interferon; IL, interleukin; MHC, major histocompatibility complex; TCR, T-cell receptor.</p></div></div><div class=section><a name=d77711e318 class=n-a></a><h3 class=section-title>1. Nucleic acid/DNA/mRNA vaccines</h3><p class="" id=d77711e323>The use of nucleic acids with the hope of developing gene therapies to correct any mutations or deficiencies or vaccines to induce specific antibody or T-cell responses against a pathogen (prophylactic vaccines) or a tumor antigen (cancer vaccines) was one of the highlighted fields in biomedical advances in 1990s. The concept of using non-live vaccines offers an opportunity to induce both humoral and cellular immunity without any concern of introducing infectious organisms that can potentially cause the illness in the vaccine recipients or unintended individuals.</p><p class="" id=d77711e326>Typically, a DNA vaccine is prepared by inserting the gene sequence of interest into a plasmid backbone that needs to be expanded and purified for administration via intradermal, subcutaneous, or intramuscular routes<sup><a href="#ref-30">30</a></sup>. When the plasmid enters the residential APCs or surrounding cells (such as myocytes), transcription occurs, resulting in expression of the protein of interest. The cell machinery provides post-translational modifications to the antigen in a manner similar to that in target cells of the vaccine. APCs play a dominant role in the effect of DNA vaccines by presenting the processed peptides on major histocompatibility complex (MHC) class I molecules either from a direct transfection or through cross-presentation of antigens taken up by phagocytosis of transfected cells<sup><a href="#ref-31">31</a></sup>. Also, secreted tumor antigens are processed by the endocytic pathway. Then antigen-loaded APCs travel to a draining lymph node (DLN) to present the antigen to naïve T cells with co-stimulatory molecules to induce T-cell expansion, cytokine secretion, or interaction with B cells. If the vaccine is administered intramuscularly, transfected muscle cells can also present the peptide-MHC complexes, increasing the chances of T-cell expansion, although preclinical evidence suggests that the relevant presentation is primarily by professional APCs in the DLNs<sup><a href="#ref-32">32</a></sup>. Another approach is to use DNA priming followed by a boost such as modified vaccinia Ankara (MVA) or a canarypox vector, as was researched originally in HIV vaccines<sup><a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Variations in delivery methods, including electroporation, that can deliver the plasmid along with other elements (such as toxoids or cytokines) and the use of xenogeneic DNA to enhance immune response have been studied and translated to clinical trials in solid tumors, including melanoma and prostate cancer<sup><a href="#ref-35">35</a>–<a href="#ref-39">39</a></sup>. In veterinary medicine, DNA vaccines targeting cancer have been licensed in a number of solid tumors. Accumulated information from the animals may contribute to the development of next-generation vaccine platforms<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a></sup>.</p><p class="" id=d77711e363>Even though DNA vaccines have shown immune responses in humans, the potency is still limited. The development of novel technologies in the delivery of nucleic acids, such as hydrophobic peptide mix, gene gun, or electroporation, can be incorporated to enhance the efficiency<sup><a href="#ref-39">39</a>,<a href="#ref-42">42</a>,<a href="#ref-43">43</a></sup>. Large batch manufacturing and a long shelf life make a DNA vaccine attractive to the community practice setting, not limiting the treatment opportunities to cutting-edge research centers, in contrast to some other personalized vaccine strategies. The other significant benefit of a DNA vaccine is the versatile construction that enables the developer to include encoding of optional safety features instead of using any intact viral particles. However, integration to cellular DNA, the theoretical risk of antibiotic resistance due to selection markers in the plasmid, and the development of autoimmune conditions due to autoantibody production have yet to be addressed. Guidelines from the regulatory groups in the European Medicines Agency, the World Health Organization, or the FDA are available to address such safety concerns about developing DNA vaccines but those guidelines are focused on preventive vaccines for infectious organisms<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>.</p><p class="" id=d77711e383>In a study of patients with metastatic melanoma (ClinicalTrials.gov identifier: NCT02035956), Sahin <i>et al</i>. analyzed the mutated neoepitopes, prioritized by predicted MHC affinity, and treated the cancers with up to 10 neoepitope-encoding mRNAs<sup><a href="#ref-47">47</a></sup>. About 60% of the patients developed <i>de novo</i> immune responses and the majority were CD4 responses. Tumor tissue sections showed neoantigen-specific killing by vaccine-induced T cells. The authors also described objective tumor responses, decreased cumulative metastasis, and sustained survival in selected patients. This study supports a newer concept of cancer vaccines using nucleic acids.</p></div><div class=section><a name=d77711e398 class=n-a></a><h3 class=section-title>2. Peptides and proteins</h3><p class="" id=d77711e403>Synthetic peptides have been used successfully in the induction of tumor-specific T-cell responses in clinical settings against both microbials and cancer<sup><a href="#ref-48">48</a></sup>. The use of peptides compared with whole cell lysates or protein has an advantage that only the epitopes of interest can be delivered to the immune system instead of overloading immunologic pathways with irrelevant antigens that might compete with the relevant epitopes or might induce autoimmune responses. Also, using only T-cell epitopes can avoid the danger of anaphylaxis associated with antibody responses by avoiding B-cell epitopes. Sometimes, the peptides require modifications to allow enhanced binding to MHC molecules to increase the immunogenicity, a process called epitope enhancement<sup><a href="#ref-49">49</a></sup>. Often, a few amino acids are added or mutated to enhance the immunogenicity and modulate the amphiphilicity and these changes have been shown to either enhance or inhibit anti-tumor T-cell responses<sup><a href="#ref-50">50</a></sup>. Vaccines using xenogeneic peptide/protein by themselves or loaded to DCs can be a further extension of enhanced immunogenicity originating from the difference in xenogeneic amino acid sequences while having the majority in common<sup><a href="#ref-40">40</a>,<a href="#ref-51">51</a></sup>. Peptides can be encapsulated in particles such as liposomes or conjugated to adjuvants to optimize the antigen uptake by specialized APCs for the MHC class I and II presentation to CD8<sup>+</sup> cytotoxic or CD4<sup>+</sup> helper T cells, respectively, and such technologies have been translated to clinical trials in both hematologic (ClinicalTrials.gov identifier: NCT03349450) and solid cancers<sup><a href="#ref-52">52</a>–<a href="#ref-56">56</a></sup>. It is relatively easy to add or substitute peptides for other epitopes compared with adoptive cell therapies such as chimeric antigen receptor (CAR) T cells or TCR-transgenic T cells, which are harder to adapt to antigen loss or alteration<sup><a href="#ref-57">57</a>–<a href="#ref-61">61</a></sup>. Using synthetic long peptides (SLPs) of 15 to 30 amino acids has been advocated by some groups who propose that professional APC-processed SLP can more efficiently induce anti-tumor responses than direct presentation of shorter peptides to the cytotoxic T cells, that can be mediated by non-professional APCs that lack costimulation<sup><a href="#ref-62">62</a>,<a href="#ref-63">63</a></sup>. Melief <i>et al</i>. have demonstrated such a concept in several clinical trials focused on human papilloma virus (HPV)-associated cancers, and vaccination using SLP has been widely applied in various solid tumors<sup><a href="#ref-64">64</a>–<a href="#ref-70">70</a></sup>. At the same time, shorter peptide vaccines have also been tested clinically in HPV-related disease and have been shown to be immunogenic<sup><a href="#ref-71">71</a></sup>. Idiotype vaccination in B-cell malignancy is another unique concept of targeting tumor-specific antigens in the form of idiotype produced uniquely by the malignant B cells or plasma cells<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. The challenge is the limited knowledge in intracellular processing and methods of tracking it in humans when the limited data are based largely on animal, especially murine, models. MHC class I processing involves endoplasmic reticulum aminopeptidases, cytosolic proteasomes, and peptidases, whereas MHC class II peptide production and processing take place in endolysosomal compartments involving cathepsin-like proteases<sup><a href="#ref-74">74</a></sup>. The process of cross-presentation allows exogenous antigens, which normally go through the MHC class II pathway, to be processed via the MHC class I pathway to trigger a cytotoxic CD8 T-cell response<sup><a href="#ref-75">75</a></sup>. Sometimes, endosomal proteases can affect epitope expression during cross-presentation<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>.</p><p class="" id=d77711e490>Clinical trials using shared tumor antigens have been safe and immunogenic in many studies but so far have not been successful in showing clinic benefit sufficient for FDA approval. GV1001 against a telomerase peptide (TeloVac) for advanced pancreatic cancer combined with chemotherapy failed to show improved overall survival in a phase III trial<sup><a href="#ref-78">78</a></sup>. Several other phase III trials, including studies targeting a MUC1 antigen (tecemotide, START trial) and EGFRVIIII in glioblastoma multiforme (rindopepimut, CDX-110, ACT III study), also failed to show improvement in overall survival despite high expectations when they went into advanced clinical studies<sup><a href="#ref-79">79</a>,<a href="#ref-80">80</a></sup>. The strategy to include multiple epitopes in one vaccine did not result in any superior results in advanced pancreatic cancer or renal cell carcinoma, indicating the serious need for better strategies to overcome several immunologic hurdles to control the cancer. Personalized peptide vaccines targeting neoantigens are among newer efforts to liberate trammeled immune responses against cancer<sup><a href="#ref-25">25</a></sup>.</p></div><div class=section><a name=d77711e509 class=n-a></a><h3 class=section-title>3. Microbial vectors and non-bacterial human pathogens, including viruses and helminths</h3><p class="" id=d77711e514>Microbes can function even in necrotic tissues, and the immune modulatory effect by the microbes can be an additional benefit added to the direct killing of cancer cells. Using bacteria or their products in cancer treatment goes back to 1890s, when Coley described the accidental finding of an inoperable case of sarcoma that improved with erysipelas; that led to treatment with inoculation of Streptococcus and <i>Bacillus prodigiosus</i>, now known as <i>Serratia marcescens</i><sup><a href="#ref-81">81</a></sup>. In his reports, he described the difficulties in inducing meaningful infection from the inoculation, the clinical course after inoculation of “Coley’s toxin”, and the regression of inoperable tumor that lasted several years in one of the patients. Since then, cancer immunotherapies have used various bacteria or their products, such as <i>Clostridium novyi</i>, <i>Listeria monocytogenes</i> (Lm), and <i>Salmonella typhimurium</i><sup><a href="#ref-82">82</a>–<a href="#ref-86">86</a></sup>. Several organisms have been tested either to serve as a vector purely to express tumor antigens or in combination with DCs or other adjuvants. In addition to those listed above, shigella and bacillus Calmette–Guérin (BCG) among bacteria, and vaccinia, lentivirus, adenovirus, yellow fever, and HPV among viruses are well-known examples of microbial vaccine vectors.</p><p class="" id=d77711e542>On another front, microbiome research in cancer and immunology has gained momentum in the past decade, leading to versatile approaches in using the microbiome, including the consideration of normal flora such as <i>Lactobacilli</i> as vectors for gynecologic cancer. Besides direct anti-cancer effects of the infection, infection of the tumor tissue with facultative anaerobes can enhance the antigenicity of tumors that otherwise could have been tolerogenic or poorly antigenic while driving the alteration in the immune subsets in a pro-inflammatory microenvironment<sup><a href="#ref-87">87</a>,<a href="#ref-88">88</a></sup>.</p><p class="" id=d77711e555>The changes in immune landscape in the use of bacterial cancer vaccines are noteworthy. MDSCs, tumor-associated macrophages, tumor-entrained neutrophils, and tolerogenic DCs are all myeloid cells that are immune-suppressive and found during tumor growth in both primary and metastatic lesions. Monocytes that are attracted to the tumor generally differentiate into macrophages, typically M2 macrophages that are characterized by arginase 1 (Arg1) expression and IL-10 known as immunosuppressive markers that contribute to immune evasion of cancer, whereas M1 macrophages contributing to anti-tumor activity express nitric oxide synthase (NOS2) and secret tumor necrosis factor-alpha (TNFα). Injection of attenuated <i>S. typhimurium</i> into HER2/neu-expressing CT26 tumors in a mouse model showed the shift to mature phenotype in macrophages in the tumor or spleen. Injection of attenuated Lm to an ID8-Defb29/Vegf-A ovarian carcinoma mouse model led to increased macrophage infiltrates in the tumor, favoring an M1 profile. These findings suggest that bacterial vaccines can reprogram the pro-inflammatory nature of cells and influence M1/M2 phenotype-specific differentiation<sup><a href="#ref-89">89</a></sup>. Melanoma cells infected with wild-type Lm can differentiate into professional APCs that express mature DC markers such as CD11c, CD40, CD83, and MHC class II<sup><a href="#ref-90">90</a></sup>. These findings suggest how pathogens can stimulate the immune function via co-stimulatory molecules involving Toll-like receptor (TLR) signaling pathways to activate killer T-cell and NK cell activities to kill tumor cells. On the other hand, tumor-associated neutrophils (TANs) are also of importance in the research of cancer vaccines using bacteria. Vendrell <i>et al</i>. reported increased recruitment of TANs after the injection of <i>Salmonella typhi</i> in a mouse model of breast cancer<sup><a href="#ref-91">91</a></sup>. TANs can alter the tumor microenvironment (TME) by secreting inflammatory cytokines such as IFNγ and TNFα that potentiate the local immune infiltrates and systemic response. Salmonella strains that are engineered to express such inflammatory cytokines have shown enhanced anti-tumor activity <i>in vivo</i>. In regard to T-cell responses, injection of attenuated Salmonella species resulted in increased Th1 phenotype CD4 T cells in tumor infiltrates, slower tumor growth, and improved host survival in mice<sup><a href="#ref-92">92</a></sup>. These effects were decreased at least in part in a T cell–depleted mouse model, suggesting the requirement for (presumably cytotoxic) T cells in the mechanism of action. Similar observations were reported with Lm and the parasite <i>Toxoplasma gondii</i><sup><a href="#ref-93">93</a></sup>. Bacterial vaccines can further modulate the TME by decreasing the expression of PD-1 in tumor-infiltrating lymphocytes (TILs), inducing central and effector memory T cells, and reducing MDSC immunosuppressive potential. Several strains of attenuated or avirulent Lm strains such as replication-deficient Lm∆dal∆dat (Lmdd) have been tried to activate MHC class I and II pathways and also to induce antigen-specific T lymphocytes<sup><a href="#ref-94">94</a></sup>. Virulence factor listeriolysin O (LLO) protein is known to boost the immune reaction by inducing IL-12, IL-18, and IFNγ and functions as a naturally occurring adjuvant when delivering the tumor antigens<sup><a href="#ref-95">95</a></sup> and can improve ratios of CD8<sup>+</sup> T cells to regulatory T cells<sup><a href="#ref-96">96</a></sup>. So far, Lm-based vaccines have been brought into clinical trials for several solid and hematologic cancers, including HPV-associated cervical cancer, melanoma, breast cancer, pancreatic cancer, and lymphoma.</p><p class="" id=d77711e609>Aside from bacterial or yeast platforms, the viral platform of cancer vaccines has its own vast ground. Many attenuated or less virulent related viruses targeting as measles, mumps, rubella, smallpox, and polio have been used successfully to prevent or decrease the severity of viral illness by inducing protective immunity in the history of modern medicine. With the advancement of genetic engineering, these viruses can also be modified as vectors to deliver and express the antigens that will elicit immune responses even in tumors that are not immunogenic by themselves during the natural history of the specific cancer type. Viral particles can express <i>in situ</i> molecules that will serve as pathogen-associated molecular patterns to increase the possibility that a tumor-associated antigen (TAA) will be presented to the immune system. Activation of TLRs is believed to play a critical role in increased anti-tumor activity in therapies using viruses<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup>. Viral vectors used in cancer vaccines can deliver the TAA, with or without co-stimulatory molecules or cytokines, that will be processed in the MHC class I pathway and produce epitopes expressed on the surface of the infected cells with MHC I, and/or with MHC class II if an APC is infected. In the case of non-lysing virus, delivery of a TAA alone might not generate enough signals for tumor cell killing. With non-lysing virus, co-delivery of a co-stimulatory molecule or cytokines can increase the chance of recruitment of professional APCs. In either case, replicating viruses at the injection site cause pro-inflammatory responses mimicking the immune response against infecting virus in non-cancerous tissues that can result in cancer cell death.</p><p class="" id=d77711e623>Adenoviruses, especially replication-incompetent Ad2 and Ad5, have been popular to deliver TAAs with or without co-stimulatory molecules<sup><a href="#ref-99">99</a></sup>. However, the majority of adults have developed immunity from long-term environmental exposure to adenoviruses, and the immune response and clinical effect were minimal because of pre-existing immunity at least in part. Poxviruses have the advantage as pre-existing immunity against poxvirus exists only in patients who were exposed to vaccinia virus. Viral tropism of the members of this family to directly infect APCs is another advantage<sup><a href="#ref-100">100</a></sup>. MVA is a proprietary agent that was produced by more than 500 culture passages of vaccinia in chicken embryo fibroblasts. During the passages, MVA became highly attenuated as it lost many poxviral genes and replicative potential in most mammalian cells. A recombinant MVA-expressing human 5T4 (MVA-h5T4), called TroVax for metastatic castration-resistant prostate cancer, and a recombinant attenuated vaccinia virus (rVV) vaccine or fowlpox virus (rFV) against human carcinoembryonic antigen (c-VV-CEA) with or without a triad of co-stimulatory adhesion molecules (TRICOM) are great examples that were tested in the clinical setting<sup><a href="#ref-101">101</a>,<a href="#ref-102">102</a></sup>. The TRICOM vector expresses three co-stimulatory molecules—CD54 (ICAM-1), CD58 (LFA3), and CD80 (B7.1)—co-expressed in the recombinant virus, and the triple combination was found to be more effective than any single one of these molecules<sup><a href="#ref-103">103</a></sup>. Examples of intelligently designed heterologous prime-boost strategy can again be found in a vaccinia prime–fowlpox boost, PANVAC encoding CEA and MUC1 alongside TRICOM<sup><a href="#ref-104">104</a></sup>. Because the vaccinia vector induces immunity against itself but not against the fowlpox vector, which also does not induce immunity to itself, it is possible to achieve a better response by priming first with the vaccinia vector and then boosting repeatedly with the fowlpox vector. Thus, a heterologous prime boost can be more effective than a homologous prime boost<sup><a href="#ref-105">105</a></sup>. PROSTVAC used priming with rVV-PSA-TRICOM followed by rFV-PSA-TRICOM to deter any neutralizing antibody responses and facilitate antigen-specific T-cell responses<sup><a href="#ref-106">106</a></sup>. Despite promising phase II results, a phase III randomized trial of PROSTVAC as a single agent did not meet its endpoints to show improved overall survival in planned interim analysis in patients with minimally symptomatic metastatic castration-resistant prostate cancer, and combination trials are ongoing<sup><a href="#ref-107">107</a>,<a href="#ref-108">108</a></sup>.</p></div><div class=section><a name=d77711e666 class=n-a></a><h3 class=section-title>4. Dendritic cell–based vaccines</h3><p class="" id=d77711e671>DC-based vaccines have several advantages despite their inherent logistic problems<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup>. DC maturation is often defective in patients with cancer and this is due in part to cytokines such as vascular endothelial growth factor (VEGF), which induces STAT3 expression and inhibits maturation<sup><a href="#ref-111">111</a>–<a href="#ref-113">113</a></sup>. Thus, antigen presentation can be defective in these patients, resulting in poor induction of T-cell responses. DC vaccines can overcome this problem in patients with cancer by starting from DC precursors, such as elutriated monocytes, which then are matured <i>in vitro</i>, away from the negative influences of the cancer environment<sup><a href="#ref-22">22</a>,<a href="#ref-114">114</a></sup>. A second related advantage is that the DCs can be matured <i>in vitro</i> to induce higher levels of co-stimulatory molecules or MHC molecules or both, making them more immunogenic<sup><a href="#ref-109">109</a>,<a href="#ref-115">115</a></sup>. A third advantage is that viral vectors can be used to transduce the DCs to express tumor antigens without neutralization by pre-existing anti-viral antibodies<sup><a href="#ref-116">116</a></sup>.</p><p class="" id=d77711e713>Even though DC-based vaccination has been a popular platform to elicit immune responses, there is no consensus on how to optimize the preparation for consistent or durable responses. Also, handling individual patient’s cells can be an obstacle in reducing the cost and simplifying the delivery process. To tackle this issue, understanding the biology of DCs is essential. DCs are a heterogeneous group of specialized APCs from the same bone marrow progenitors as monocytes, called monocyte and DC progenitors, that differentiate into three major subsets of DCs: CD1c DCs, which are predominant; CD141<sup>+</sup> DCs; and plasmacytoid DCs (pDCs)<sup><a href="#ref-117">117</a>–<a href="#ref-119">119</a></sup>. The first two are called conventional DCs (cDCs). pDCs play a major role in viral infections by rapid cross-presentation of antigens and production of up to 1000-fold more type I IFNs (α and β). Human DCs lack lineage markers but express MHC class II. Whereas cDCs can be found in almost all peripheral tissues, including lymphoid organs, pDCs are discovered mostly in T-cell areas of lymphoid organs, such as lymph nodes, spleen, bone marrow, Peyer’s patches, tonsils, thymus, and liver. DCs can activate or negate anti-tumor T-cell responses by affecting killer or regulatory T–cell activation<sup><a href="#ref-120">120</a></sup>. Mobilized CD34 precursors can be differentiated into monocyte-derived DCs (MDDCs) that yield several different types of myeloid cells, including all three major types of DCs, as a consequence of working with higher levels of progenitor cells. It may be important to manipulate each subset individually to improve immunogenicity<sup><a href="#ref-121">121</a></sup>, and some groups use bead-selected DCs. For example, in some studies, Langerhans-like DCs induced with IL-15 were found to be more effective at eliciting CD8<sup>+</sup> T-cell responses<sup><a href="#ref-122">122</a></sup>. Moreover, activation of Langerhans cells with a cytokine combination could induce immunity against HPV that then could be boosted with a therapeutic vaccine<sup><a href="#ref-123">123</a></sup>. Similarly, the BATF3-expressing DC subset may be critical for cross-priming and for reactivating a memory anti-tumor response<sup><a href="#ref-124">124</a></sup>. On the other hand, immature DCs have been found to induce regulatory T cells<sup><a href="#ref-125">125</a></sup>.</p><p class="" id=d77711e754>The first and only FDA-approved cell-based therapy for metastatic prostate cancer, sipuleucel-T, contains a variety of cells, including B cells, monocytes, DCs, and NK cells, that are cultured and processed in the presence of prostatic acid phosphatase (PAP) fused with granulocyte-macrophage colony-stimulating factor (GM-CSF) for 2 days following leukapheresis in designated apheresis centers<sup><a href="#ref-1">1</a>,<a href="#ref-126">126</a></sup>. Patients receive up to three doses of freshly prepared products at 2-week intervals. The most commonly used method is to differentiate the monocytes from peripheral blood mononuclear cells (PBMCs) into DCs, so-called MDDCs. PBMCs that are monocyte-elutriated with or without CD14 bead selection are differentiated into immature CD14<sup>−</sup>CD83<sup>−</sup> DCs by culturing in IL-4– and GM-CSF–supplemented culture media usually for 3 to 5 days followed by antigen loading for 24 to 48 hours. DCs then can be matured with lipopolysaccharide (LPS) and IFNγ or with a cytokine cocktail<sup><a href="#ref-22">22</a>,<a href="#ref-109">109</a></sup>. Matured DCs are harvested for the delivery. However, owing to the labor-intensive and costly manufacturing process, aliquoting and freezing individual doses and use of automated closed culture systems are being actively investigated. For allogeneic sources of DCs, cDCs of umbilical cord blood origin can be one option to meet the need for unrelated healthy donors. However, the immune functions of the DCs in umbilical cord are questioned and the use of HLA-half matched allogeneic DCs has not been successfully translated to the clinic yet<sup><a href="#ref-127">127</a>,<a href="#ref-128">128</a></sup>.</p><p class="" id=d77711e784>Several ways have been adopted for antigen loading. As DCs are professional APCs, loading with synthetic peptides, protein, tumor cell lysates, and RNAs and even direct infection with microbes are viable options. APCs fused with tumor cells, whether from an autologous or allogeneic source, were the prototype of cancer vaccine from the 1990s, when the approach was first described<sup><a href="#ref-129">129</a>,<a href="#ref-130">130</a></sup>. Despite high production costs due to patient-specific therapies, there have been continued efforts to translate DC vaccines to clinical trials in both solid and hematologic cancers<sup><a href="#ref-114">114</a>,<a href="#ref-131">131</a>–<a href="#ref-133">133</a></sup>. Using whole lysates of either autologous or allogeneic tumor cells can lead to the presentation of multiple epitopes for a prolonged period, enabling longer antigen presentation that will allow both CD4 and CD8 T-cell responses. Wild-type or attenuated pathogens can serve as vectors to carry the genes encoding TAA to be expressed in DCs. Transfection of the nucleic acids encoding TAAs can induce potent TAA-specific T-cell responses at least <i>in vivo</i>. For example, mRNA can be transfected by electroporation (renal cell carcinoma, ClinicalTrials.gov identifier: NCT01582672; advanced melanoma, phase II, ClinicalTrials.gov identifier: NCT01302496) or a cationic lipid such as DOTAP<sup><a href="#ref-134">134</a>–<a href="#ref-136">136</a></sup>. Alternatively, retroviral transduction has been used to facilitate and prolong stable TAA expression. Viral vectors such as lentivirus or adenovirus have been employed in several preclinical and clinical studies with DC vaccines because of the advantage of transducing non-dividing cells<sup><a href="#ref-137">137</a>–<a href="#ref-139">139</a></sup>. In regard to the issue of adequate involvement of CD4 cells to enhance CD8 cell response in DC-based vaccines, adding other antigens such as keyhole limpet hemocyanin (KLH) as a target for helper T cells that can facilitate the antigen presentation and migration to the DLNs is an option<sup><a href="#ref-22">22</a>,<a href="#ref-115">115</a></sup>.</p><p class="" id=d77711e830>As the manufacturing and quality control of the DC vaccines are highly variable, development of large-scale studies is limited and the interpretation of smaller-scale studies is often difficult<sup><a href="#ref-140">140</a>–<a href="#ref-142">142</a></sup>. Also, there is no consensus in measuring the correlatives to evaluate the vaccines. How and what cytokines or markers should be measured and in which samples? For example, is measuring the cytokine from the serum or by intracellular cytokine staining a better indicator of DC functions or activation? Analysis of the activation of vaccinated DCs showed a relationship with clinical benefit, and associated predictive markers of the most effective DCs have been reported<sup><a href="#ref-115">115</a></sup>. Given the limited consensus, ground-breaking developments in manufacturing, quality control, and optimized delivery of the vaccine to overcome the hurdle of cross-priming and TME are still needed.</p><p class="" id=d77711e844>A whole allogeneic pancreatic cell line secreting GM-CSF, called GVAX, is another strategy to use DCs <i>in vivo</i> that stimulate the accrual and function of APCs to the vaccine site. This strategy can potentially involve all DC subsets, not only the subsets in the apheresis product, and result in increased T-cell infiltration and development of tertiary lymphoid structures even in a so-called “non-immunogenic” tumor such as pancreatic cancer or prostate cancer<sup><a href="#ref-143">143</a>,<a href="#ref-144">144</a></sup>. This method has the merit of not involving the labor-intensive and expensive <i>ex vivo</i> manufacturing process. However, a phase IIb study of a combination of GVAX and a mesothelin-expressing live-attenuated listeria vaccine CRS-207 did not show improved overall survival<sup><a href="#ref-145">145</a>,<a href="#ref-146">146</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e871>Cancer vaccines in prophylaxis of cancer</h2><p class="" id=d77711e874>Current data support the concept that cancer vaccines can induce more efficient immune responses and improved control of disease when the tumor burden is not overwhelmingly high, because targeting low tumor burden avoids immune suppressive effects of tumor cells and the cumulative impacts of cytotoxic therapies on immune function. In this sense, investigation of cancer vaccines in the prophylactic or preventive setting is reasonable, in both primary and secondary prevention<sup><a href="#ref-147">147</a>–<a href="#ref-151">151</a></sup>. However, because a prophylactic vaccine is used for healthy people rather than cancer patients who have exhausted other therapies, it is critical to avoid inducing autoimmune responses or other adverse effects. Thus, choice of antigens unique to tumors that are not expressed in normal tissue is essential. Intralesional delivery of a DC vaccine into ductal carcinoma <i>in situ</i> targeting HER2/neu showed a decline or disappearance of HER2/neu expression<sup><a href="#ref-152">152</a></sup>. Prophylactic vaccines in high-risk patients with Lynch syndrome or colorectal cancer with microsatellite instability (MSI) are under study. NCT01885702 is studying autologous DC vaccines loaded with CEA and specific frameshift-derived neoantigen peptides in patients with either colorectal cancer that is MSI-unstable or carriers of a germline MMR-gene mutation with no signs of cancer, who are HLA-A2.1<sup>+</sup>. Analysis of the blood from enrolled patients showed antigen-specific T cells against several neoepitopes, including epitopes from germline mutations, in immune function–related genes such as TGFβ receptor and caspases, supporting the rationale of a prophylactic role of cancer vaccines in high-risk patients, although final results are not yet posted. In addition, a considerable body of evidence suggests the sharing of some tumor antigens, such as hypoglycosylated MUC1, with other inflammatory diseases<sup><a href="#ref-150">150</a>,<a href="#ref-153">153</a></sup>. For example, epidemiologic studies suggest a reduced risk of breast cancer in patients with a history of mastitis. Clinical studies to test this hypothesis are under way.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e904>Vaccine delivery–related issues: routes of administration, accessibility of cancer vaccines, and schedule</h2><p class="" id=d77711e907>Several routes of injection have been studied. Unlike vaccination against infectious organisms, the mucosal route has rarely been used. Most vaccines have been studied using a parenteral route, primarily subcutaneous, intradermal, or intramuscular, with less favor for intravenous delivery because of low immune response and concerns about direct organ toxicity or anaphylaxis. Intratumoral injection has been studied predominantly in melanoma and brain tumors often with local conditioning with cytokine or toxoid but also in several solid tumors in case of vectors of lytic or direct cytopathic potential<sup><a href="#ref-29">29</a>,<a href="#ref-154">154</a>,<a href="#ref-155">155</a></sup>. The immunologic properties and expected mechanism of immune activation have led investigators to individual choice among subcutaneous, intradermal, intramuscular injection, and intravenous infusion. In theory, intravenous infusion of DCs can deliver DCs to secondary lymphoid tissue rapidly and intratumoral injection has an advantage of modulating the TME. However, intradermal delivery of DCs was most effective in animal models<sup><a href="#ref-156">156</a>,<a href="#ref-157">157</a></sup>. In general, relatively few DCs were detected in the DLNs when they were intradermally or intratumorally administered. Direct injection into a single or multiple lymph nodes did not show any improvement compared with intradermal injection. Other systemic or local intervention, including cytokine or TLR agonist administration to improve the DC and T-cell homing or enhance local inflammation, might be helpful<sup><a href="#ref-158">158</a></sup>. Overall, the chemical and immunologic nature of the vaccine composition that can result in local tissue damage or altered immunologic cascade should be considered to determine the optimal route and the depth of injection to maximize safety and immunogenicity. Vaccine route may also affect the balance between responses of circulating versus tissue-resident memory T cells, as both may be necessary for efficacy<sup><a href="#ref-124">124</a>,<a href="#ref-159">159</a>,<a href="#ref-160">160</a></sup>.</p><p class="" id=d77711e941>Other than the vaccine platform–specific route of administration, there are issues related to vaccine delivery. Availability of cancer vaccines is one of those. Some vaccines are facility-dependent in their manufacturing or delivery, and it is hard to expand their use to the community setting outside cutting-edge research facilities. To expand the use of cancer vaccines successfully, the vaccine platform should be designed with the widening of accessibility in mind. Optimum interval spacing or doses of cancer vaccines are largely unknown because of a lack of information from clinically successful cancer vaccines in contrast to vaccines against infectious organisms.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e948>Summary</h2><p class="" id=d77711e951>During the past 30 years of modern cancer vaccine development, various vaccine platforms have been tried in clinical trials based on successful preclinical models. Sources of tumor antigen can be synthetic (nucleic acids or peptides), viral, or microbial vectors or autologous or allogeneic tumor cell–derived cells, tumor cell lysates or RNA. Some platforms use infectious organisms to present the tumor antigen to APCs <i>in vivo</i>, whereas some researchers use DCs <i>in vitro</i> for antigen loading. Co-stimulatory molecules and cytokines have been tried, but no clear consensus has been made on the optimal choice. However, a prioritized set of immunomodulatory molecules to use as vaccine adjuvants has been developed by a National Cancer Institute working group<sup><a href="#ref-161">161</a></sup>. The majority of the vaccines that were successful in inducing immunologic anti-tumor response could not match that success in the clinical response, indicating the need for improved vaccine platforms and probably combinations with checkpoint inhibitors or other methods to block immune suppression by cancer.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d77711e967>Conclusions</h2><p class="" id=d77711e970>Cancer immunotherapy has established its position as the fourth pillar of anti-cancer therapy, complementing surgery, chemotherapy, and radiation. Following monoclonal antibodies against tumor antigens, checkpoint inhibitors, and adoptive cell therapy, cancer vaccine research is poised to achieve more breakthrough discoveries. Synergistic effects in combination therapy with other strategies will be critical when current data clearly indicate that the vaccine alone is not sufficient to control clinically advanced cancers. Not all tumors are immunogenic by themselves (“cold tumors”), and the use of cancer vaccines to turn the tumor “hot” by inducing immune responses that then can be amplified by blockers of negative regulatory immunologic signals will make “cold” tumors more susceptible to checkpoint blockade and other inhibitors of immunoregulatory mechanisms. Cancer vaccines can contribute to overcoming the current issues of lower-than-desired response rates and efficacy in current cancer immunotherapy regimens.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d77711e1 class=n-a></a><h2 class=main-title id=d78190>Grant information</h2><p>This work was supported by the National Cancer Institute.</p><p><i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i></p></div><div class=back-section><a name=d77711e977 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d78740>References</h2><div class="section ref-list"><a name=d77711e977 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/4568961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e984 class=n-a></a>Kantoff PW, Higano CS, Shore ND, <i> et al.</i>: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>N Engl J Med.</i> 2010; <b>363</b>(5): 411–22. <a target=xrefwindow id=d77711e995 href="http://www.ncbi.nlm.nih.gov/pubmed/20818862">PubMed Abstract </a> | <a target=xrefwindow id=d77711e998 href="https://doi.org/10.1056/NEJMoa1001294">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/4568961">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d77711e1011 class=n-a></a>Berzofsky JA, Terabe M, Wood LV: Strategies to use immune modulators in therapeutic vaccines against cancer. <i>Semin Oncol.</i> 2012; <b>39</b>(3): 348–57. <a target=xrefwindow id=d77711e1019 href="http://www.ncbi.nlm.nih.gov/pubmed/22595057">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1022 href="https://doi.org/10.1053/j.seminoncol.2012.02.002">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3356566">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d77711e1034 class=n-a></a>Parchment RE, Voth AR, Doroshow JH, <i> et al.</i>: Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <i>Semin Oncol.</i> 2016; <b>43</b>(4): 501–13. <a target=xrefwindow id=d77711e1045 href="http://www.ncbi.nlm.nih.gov/pubmed/27663482">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1048 href="https://doi.org/10.1053/j.seminoncol.2016.06.008">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725241175"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1057 class=n-a></a>Snyder A, Makarov V, Merghoub T, <i> et al.</i>: Genetic basis for clinical response to CTLA-4 blockade in melanoma. <i>N Engl J Med.</i> 2014; <b>371</b>(23): 2189–99. <a target=xrefwindow id=d77711e1068 href="http://www.ncbi.nlm.nih.gov/pubmed/25409260">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1071 href="https://doi.org/10.1056/NEJMoa1406498">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1075 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4315319">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725241175">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725780109"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1088 class=n-a></a>van Allen EM, Miao D, Schilling B, <i> et al.</i>: Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science.</i> 2015; <b>350</b>(6257): 207–11. <a target=xrefwindow id=d77711e1099 href="http://www.ncbi.nlm.nih.gov/pubmed/26359337">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1102 href="https://doi.org/10.1126/science.aad0095">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1106 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5054517">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725780109">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726228392"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1120 class=n-a></a>Hugo W, Zaretsky JM, Sun L, <i> et al.</i>: Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell.</i> 2016; <b>165</b>(1): 35–44. <a target=xrefwindow id=d77711e1131 href="http://www.ncbi.nlm.nih.gov/pubmed/26997480">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1134 href="https://doi.org/10.1016/j.cell.2016.02.065">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1138 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4808437">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726228392">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730845025"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1151 class=n-a></a>Ribas A, Dummer R, Puzanov I, <i> et al.</i>: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell.</i> 2017; <b>170</b>(6): 1109–1119.e10. <a target=xrefwindow id=d77711e1162 href="http://www.ncbi.nlm.nih.gov/pubmed/28886381">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1165 href="https://doi.org/10.1016/j.cell.2017.08.027">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730845025">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725249074"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1178 class=n-a></a>Tumeh PC, Harview CL, Yearley JH, <i> et al.</i>: PD-1 blockade induces responses by inhibiting adaptive immune resistance. <i>Nature.</i> 2014; <b>515</b>(7528): 568–71. <a target=xrefwindow id=d77711e1189 href="http://www.ncbi.nlm.nih.gov/pubmed/25428505">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1192 href="https://doi.org/10.1038/nature13954">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4246418">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725249074">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727748531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1209 class=n-a></a>Ayers M, Lunceford J, Nebozhyn M, <i> et al.</i>: IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. <i>J Clin Invest.</i> 2017; <b>127</b>(8): 2930–40. <a target=xrefwindow id=d77711e1220 href="http://www.ncbi.nlm.nih.gov/pubmed/28650338">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1223 href="https://doi.org/10.1172/JCI91190">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5531419">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727748531">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d77711e1240 class=n-a></a>Terabe M, Robertson FC, Clark K, <i> et al.</i>: Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. <i>Oncoimmunology.</i> 2017; <b>6</b>(5): e1308616. <a target=xrefwindow id=d77711e1251 href="http://www.ncbi.nlm.nih.gov/pubmed/28638730">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1254 href="https://doi.org/10.1080/2162402X.2017.1308616">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1258 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5467996">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732660162"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1267 class=n-a></a>Mariathasan S, Turley SJ, Nickles D, <i> et al.</i>: TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature.</i> 2018; <b>554</b>(7693): 544–8. <a target=xrefwindow id=d77711e1278 href="http://www.ncbi.nlm.nih.gov/pubmed/29443960">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1281 href="https://doi.org/10.1038/nature25501">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1285 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6028240">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732660162">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732661923"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1299 class=n-a></a>Tauriello DVF, Palomo-Ponce S, Stork D, <i> et al.</i>: TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. <i>Nature.</i> 2018; <b>554</b>(7693): 538–43. <a target=xrefwindow id=d77711e1310 href="http://www.ncbi.nlm.nih.gov/pubmed/29443964">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1313 href="https://doi.org/10.1038/nature25492">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732661923">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d77711e1326 class=n-a></a>Morris JC, Tan AR, Olencki TE, <i> et al.</i>: Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. <i>PLoS One.</i> 2014; <b>9</b>(3): e90353. <a target=xrefwindow id=d77711e1337 href="http://www.ncbi.nlm.nih.gov/pubmed/24618589">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1340 href="https://doi.org/10.1371/journal.pone.0090353">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1344 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3949712">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d77711e1353 class=n-a></a>Henderson RA, Finn OJ: Human tumor antigens are ready to fly. <i>Adv Immunol.</i> 1996; <b>62</b>: 217–56. <a target=xrefwindow id=d77711e1361 href="http://www.ncbi.nlm.nih.gov/pubmed/8781270">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1364 href="https://doi.org/10.1016/S0065-2776(08)60431-9">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d77711e1373 class=n-a></a>Finn OJ: Cancer vaccines: between the idea and the reality. <i>Nat Rev Immunol.</i> 2003; <b>3</b>(8): 630–41. <a target=xrefwindow id=d77711e1381 href="http://www.ncbi.nlm.nih.gov/pubmed/12974478">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1384 href="https://doi.org/10.1038/nri1150">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d77711e1393 class=n-a></a>Cheever MA, Allison JP, Ferris AS, <i> et al.</i>: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. <i>Clin Cancer Res.</i> 2009; <b>15</b>(17): 5323–37. <a target=xrefwindow id=d77711e1404 href="http://www.ncbi.nlm.nih.gov/pubmed/19723653">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1407 href="https://doi.org/10.1158/1078-0432.CCR-09-0737">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1411 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5779623">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d77711e1420 class=n-a></a>Jerome KR, Barnd DL, Bendt KM, <i> et al.</i>: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. <i>Cancer Res.</i> 1991; <b>51</b>(11): 2908–16. <a target=xrefwindow id=d77711e1431 href="http://www.ncbi.nlm.nih.gov/pubmed/1709586">PubMed Abstract </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d77711e1441 class=n-a></a>Goydos JS, Elder E, Whiteside TL, <i> et al.</i>: A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. <i>J Surg Res.</i> 1996; <b>63</b>(1): 298–304. <a target=xrefwindow id=d77711e1452 href="http://www.ncbi.nlm.nih.gov/pubmed/8667619">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1455 href="https://doi.org/10.1006/jsre.1996.0264">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d77711e1464 class=n-a></a>Disis ML, Grabstein KH, Sleath PR, <i> et al.</i>: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. <i>Clin Cancer Res.</i> 1999; <b>5</b>(6): 1289–97. <a target=xrefwindow id=d77711e1475 href="http://www.ncbi.nlm.nih.gov/pubmed/10389911">PubMed Abstract </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d77711e1484 class=n-a></a>Peoples GE, Holmes JP, Hueman MT, <i> et al.</i>: Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. <i>Clin Cancer Res.</i> 2008; <b>14</b>(3): 797–803. <a target=xrefwindow id=d77711e1495 href="http://www.ncbi.nlm.nih.gov/pubmed/18245541">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1498 href="https://doi.org/10.1158/1078-0432.CCR-07-1448">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d77711e1507 class=n-a></a>Wolfgang CD, Essand M, Vincent JJ, <i> et al.</i>: TARP: A nuclear protein expressed in prostate and breast cancer cells derived from an alternate reading frame of the T cell receptor gamma chain locus. <i>Proc Natl Acad Sci U S A.</i> 2000; <b>97</b>(17): 9437–42. <a target=xrefwindow id=d77711e1518 href="http://www.ncbi.nlm.nih.gov/pubmed/10931945">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1521 href="https://doi.org/10.1073/pnas.160270597">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1525 href="http://www.ncbi.nlm.nih.gov/pmc/articles/16882">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d77711e1534 class=n-a></a>Wood LV, Fojo A, Roberson BD, <i> et al.</i>: TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer. <i>Oncoimmunology.</i> 2016; <b>5</b>(8): e1197459. <a target=xrefwindow id=d77711e1545 href="http://www.ncbi.nlm.nih.gov/pubmed/27622067">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1548 href="https://doi.org/10.1080/2162402X.2016.1197459">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1552 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5007958">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732882359"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1561 class=n-a></a>Sahin U, Türecit Ö: Personalized vaccines for cancer immunotherapy. <i>Science.</i> 2018; <b>359</b>(6382): 1355–60. <a target=xrefwindow id=d77711e1569 href="http://www.ncbi.nlm.nih.gov/pubmed/29567706">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1572 href="https://doi.org/10.1126/science.aar7112">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732882359">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d77711e1586 class=n-a></a>Carbone DP, Ciernik IF, Kelley MJ, <i> et al.</i>: Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. <i>J Clin Oncol.</i> 2005; <b>23</b>(22): 5099–107. <a target=xrefwindow id=d77711e1597 href="http://www.ncbi.nlm.nih.gov/pubmed/15983396">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1600 href="https://doi.org/10.1200/JCO.2005.03.158">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727775264"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1609 class=n-a></a>Ott PA, Hu Z, Keskin DB, <i> et al.</i>: An immunogenic personal neoantigen vaccine for patients with melanoma. <i>Nature.</i> 2017; <b>547</b>(7662): 217–21. <a target=xrefwindow id=d77711e1620 href="http://www.ncbi.nlm.nih.gov/pubmed/28678778">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1623 href="https://doi.org/10.1038/nature22991">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1627 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5577644">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727775264">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727430026"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1640 class=n-a></a>Khodadoust MS, Olsson N, Wagar LE, <i> et al.</i>: Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. <i>Nature.</i> 2017; <b>543</b>(7647): 723–7. <a target=xrefwindow id=d77711e1651 href="http://www.ncbi.nlm.nih.gov/pubmed/28329770">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1654 href="https://doi.org/10.1038/nature21433">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1658 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5808925">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727430026">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727499819"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1671 class=n-a></a>Stevanovic S, Pasetto A, Helman SR, <i> et al.</i>: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. <i>Science.</i> 2017; <b>356</b>(6334): 200–5. <a target=xrefwindow id=d77711e1682 href="http://www.ncbi.nlm.nih.gov/pubmed/28408606">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1685 href="https://doi.org/10.1126/science.aak9510">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1689 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6295311">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727499819">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732091698"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1702 class=n-a></a>Balachandran VP, Luksza M, Zhao JN, <i> et al.</i>: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature.</i> 2017; <b>551</b>(7681): 512–6. <a target=xrefwindow id=d77711e1713 href="http://www.ncbi.nlm.nih.gov/pubmed/29132146">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1716 href="https://doi.org/10.1038/nature24462">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1720 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6145146">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732091698">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d77711e1733 class=n-a></a>Salazar AM, Erlich RB, Mark A, <i> et al.</i>: Therapeutic <i>in situ</i> autovaccination against solid cancers with intratumoral poly-ICLC: case report, hypothesis, and clinical trial. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(8): 720–4. <a target=xrefwindow id=d77711e1747 href="http://www.ncbi.nlm.nih.gov/pubmed/24801836">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1751 href="https://doi.org/10.1158/2326-6066.CIR-14-0024">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d77711e1761 class=n-a></a>Liu MA, Ulmer JB: Gene-Based Vaccines. <i>Mol Ther.</i> 2000; <b>1</b>(6): 497–500. <a target=xrefwindow id=d77711e1769 href="http://www.ncbi.nlm.nih.gov/pubmed/10933973">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1772 href="https://doi.org/10.1006/mthe.2000.0079">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d77711e1781 class=n-a></a>Aptsiauri N, Cabrera T, Mendez R, <i> et al.</i>: Role of altered expression of HLA class I molecules in cancer progression. <i>Adv Exp Med Biol.</i> 2007; <b>601</b>: 123–31. <a target=xrefwindow id=d77711e1792 href="http://www.ncbi.nlm.nih.gov/pubmed/17712999">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1795 href="https://doi.org/10.1007/978-0-387-72005-0_13">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d77711e1804 class=n-a></a>Iwasaki A, Torres CA, Ohashi PS, <i> et al.</i>: The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. <i>J Immunol.</i> 1997; <b>159</b>(1): 11–4. <a target=xrefwindow id=d77711e1815 href="http://www.ncbi.nlm.nih.gov/pubmed/9200432">PubMed Abstract </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733277676"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1824 class=n-a></a>Vaccari M, Fourati S, Gordon SN, <i> et al.</i>: HIV vaccine candidate activation of hypoxia and the inflammasome in CD14<sup>+</sup> monocytes is associated with a decreased risk of SIV<sub>mac251</sub> acquisition. <i>Nat Med.</i> 2018; <b>24</b>(6): 847–56. <a target=xrefwindow id=d77711e1842 href="http://www.ncbi.nlm.nih.gov/pubmed/29785023">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1845 href="https://doi.org/10.1038/s41591-018-0025-7">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1848 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5992093">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733277676">F1000 Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725820531"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e1861 class=n-a></a>Sun YY, Peng S, Han L, <i> et al.</i>: Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8<sup>+</sup> T-cell-Mediated Tumor Control in the Genital Tract. <i>Clin Cancer Res.</i> 2016; <b>22</b>(3): 657–69. <a target=xrefwindow id=d77711e1875 href="http://www.ncbi.nlm.nih.gov/pubmed/26420854">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1879 href="https://doi.org/10.1158/1078-0432.CCR-15-0234">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1882 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4738102">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725820531">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d77711e1895 class=n-a></a>Valentin A, McKinnon K, Li J, <i> et al.</i>: Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. <i>Clin Immunol.</i> 2014; <b>155</b>(1): 91–107. <a target=xrefwindow id=d77711e1906 href="http://www.ncbi.nlm.nih.gov/pubmed/25229164">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1909 href="https://doi.org/10.1016/j.clim.2014.09.005">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1913 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4252823">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d77711e1923 class=n-a></a>McNeel DG, Dunphy EJ, Davies JG, <i> et al.</i>: Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. <i>J Clin Oncol.</i> 2009; <b>27</b>(25): 4047–54. <a target=xrefwindow id=d77711e1934 href="http://www.ncbi.nlm.nih.gov/pubmed/19636017">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1937 href="https://doi.org/10.1200/JCO.2008.19.9968">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1941 href="http://www.ncbi.nlm.nih.gov/pmc/articles/19636017">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d77711e1950 class=n-a></a>Wolchok JD, Yuan J, Houghton AN, <i> et al.</i>: Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. <i>Mol Ther.</i> 2007; <b>15</b>(11): 2044–50. <a target=xrefwindow id=d77711e1961 href="http://www.ncbi.nlm.nih.gov/pubmed/17726460">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1964 href="https://doi.org/10.1038/sj.mt.6300290">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d77711e1973 class=n-a></a>Ginsberg BA, Gallardo HF, Rasalan TS, <i> et al.</i>: Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. <i>Clin Cancer Res.</i> 2010; <b>16</b>(15): 4057–65. <a target=xrefwindow id=d77711e1984 href="http://www.ncbi.nlm.nih.gov/pubmed/20647477">PubMed Abstract </a> | <a target=xrefwindow id=d77711e1987 href="https://doi.org/10.1158/1078-0432.CCR-10-1093">Publisher Full Text </a> | <a target=xrefwindow id=d77711e1991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4241567">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d77711e2000 class=n-a></a>Eriksson F, Tötterman T, Maltais AK, <i> et al.</i>: DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. <i>Vaccine.</i> 2013; <b>31</b>(37): 3843–8. <a target=xrefwindow id=d77711e2011 href="http://www.ncbi.nlm.nih.gov/pubmed/23831327">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2014 href="https://doi.org/10.1016/j.vaccine.2013.06.063">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735640518"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e2023 class=n-a></a>Sarbu L, Kitchell BE, Bergman PJ: Safety of administering the canine melanoma DNA vaccine (Oncept) to cats with malignant melanoma - a retrospective study. <i>J Feline Med Surg.</i> 2016; <b>19</b>: 224–30. <a target=xrefwindow id=d77711e2031 href="http://www.ncbi.nlm.nih.gov/pubmed/26685147">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2034 href="https://doi.org/10.1177/1098612X15623319">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735640518">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d77711e2047 class=n-a></a>Bergman PJ, Camps-Palau MA, McKnight JA, <i> et al.</i>: Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. <i>Vaccine.</i> 2006; <b>24</b>(21): 4582–5. <a target=xrefwindow id=d77711e2058 href="http://www.ncbi.nlm.nih.gov/pubmed/16188351">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2061 href="https://doi.org/10.1016/j.vaccine.2005.08.027">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d77711e2071 class=n-a></a>Buchan S, Gronevik E, Mathiesen I, <i> et al.</i>: Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. <i>J Immunol.</i> 2005; <b>174</b>(10): 6292–8. <a target=xrefwindow id=d77711e2082 href="http://www.ncbi.nlm.nih.gov/pubmed/15879128">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2085 href="https://doi.org/10.4049/jimmunol.174.10.6292">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d77711e2094 class=n-a></a>Huang L, Lemos HP, Li L, <i> et al.</i>: Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. <i>J Immunol.</i> 2012; <b>188</b>(10): 4913–20. <a target=xrefwindow id=d77711e2105 href="http://www.ncbi.nlm.nih.gov/pubmed/22516958">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2108 href="https://doi.org/10.4049/jimmunol.1103668">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3349160">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d77711e2121 class=n-a></a>Drug and Device News. <i>P T.</i> 2017; <b>42</b>(9): 554–593. <a target=xrefwindow id=d77711e2129 href="http://www.ncbi.nlm.nih.gov/pubmed/28890640">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2132 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5565127">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d77711e2141 class=n-a></a>Kutzler MA, Weiner DB: DNA vaccines: ready for prime time? <i>Nat Rev Genet.</i> 2008; <b>9</b>(10): 776–88. <a target=xrefwindow id=d77711e2149 href="http://www.ncbi.nlm.nih.gov/pubmed/18781156">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2152 href="https://doi.org/10.1038/nrg2432">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2155 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4317294">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d77711e2164 class=n-a></a>Administration USFaD: Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications. <i>Biotechnol Law Rep.</i> 2007; <b>26</b>(6): <a target=xrefwindow id=d77711e2172 href="https://doi.org/10.1089/blr.2007.9905">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727775310"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e2181 class=n-a></a>Sahin U, Derhovanessian E, Miller M, <i> et al.</i>: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. <i>Nature.</i> 2017; <b>547</b>(7662): 222–226. <a target=xrefwindow id=d77711e2192 href="http://www.ncbi.nlm.nih.gov/pubmed/28678784">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2195 href="https://doi.org/10.1038/nature23003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727775310">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d77711e2209 class=n-a></a>Hos BJ, Tondini E, van Kasteren SI, <i> et al.</i>: Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. <i>Front Immunol.</i> 2018; <b>9</b>: 884. <a target=xrefwindow id=d77711e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/29755468">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2223 href="https://doi.org/10.3389/fimmu.2018.00884">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5932164">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d77711e2236 class=n-a></a>Berzofsky JA: Designing peptide vaccines to broaden recognition and enhance potency. <i>Ann N Y Acad Sci.</i> 1995; <b>754</b>: 161–8. <a target=xrefwindow id=d77711e2244 href="http://www.ncbi.nlm.nih.gov/pubmed/7625650">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2247 href="https://doi.org/10.1111/j.1749-6632.1995.tb44449.x">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d77711e2256 class=n-a></a>Cornette JL, Margalit H, Berzofsky JA, <i> et al.</i>: Periodic variation in side-chain polarities of T-cell antigenic peptides correlates with their structure and activity. <i>Proc Natl Acad Sci U S A.</i> 1995; <b>92</b>(18): 8368–72. <a target=xrefwindow id=d77711e2267 href="http://www.ncbi.nlm.nih.gov/pubmed/7667297">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2270 href="https://doi.org/10.1073/pnas.92.18.8368">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2274 href="http://www.ncbi.nlm.nih.gov/pmc/articles/41158">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d77711e2283 class=n-a></a>Fong L, Brockstedt D, Benike C, <i> et al.</i>: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. <i>J Immunol.</i> 2001; <b>167</b>(12): 7150–6. <a target=xrefwindow id=d77711e2294 href="http://www.ncbi.nlm.nih.gov/pubmed/11739538">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2297 href="https://doi.org/10.4049/jimmunol.167.12.7150">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d77711e2306 class=n-a></a>North S, Butts C: Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. <i>Expert Rev Vaccines.</i> 2005; <b>4</b>(3): 249–57. <a target=xrefwindow id=d77711e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/16026241">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2317 href="https://doi.org/10.1586/14760584.4.3.249">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d77711e2326 class=n-a></a>Dorigo O, Tanyi JL, Strauss J, <i> et al.</i>: Clinical data from the DeCidE<sup>1</sup> trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. <i>J Clin Oncol.</i> 2018; <b>36</b>: 5510. <a target=xrefwindow id=d77711e2340 href="https://doi.org/10.1200/JCO.2018.36.15_suppl.5510">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d77711e2350 class=n-a></a>Varypataki EM, Benne N, Bouwstra J, <i> et al.</i>: Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines. <i>Cancer Immunol Res.</i> 2017; <b>5</b>(3): 222–33. <a target=xrefwindow id=d77711e2361 href="http://www.ncbi.nlm.nih.gov/pubmed/28143806">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2364 href="https://doi.org/10.1158/2326-6066.CIR-16-0283">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d77711e2373 class=n-a></a>Butts C, Maksymiuk A, Goss G, <i> et al.</i>: Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. <i>J Cancer Res Clin Oncol.</i> 2011; <b>137</b>(9): 1337–42. <a target=xrefwindow id=d77711e2384 href="http://www.ncbi.nlm.nih.gov/pubmed/21744082">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2387 href="https://doi.org/10.1007/s00432-011-1003-3">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d77711e2396 class=n-a></a>Korsholm KS, Hansen J, Karlsen K, <i> et al.</i>: Induction of CD8+ T-cell responses against subunit antigens by the novel cationic liposomal CAF09 adjuvant. <i>Vaccine.</i> 2014; <b>32</b>(31): 3927–35. <a target=xrefwindow id=d77711e2407 href="http://www.ncbi.nlm.nih.gov/pubmed/24877765">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2410 href="https://doi.org/10.1016/j.vaccine.2014.05.050">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717954402"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e2419 class=n-a></a>Walter S, Weinschenk T, Stenzl A, <i> et al.</i>: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. <i>Nat Med.</i> 2012; <b>18</b>(8): 1254–61. <a target=xrefwindow id=d77711e2430 href="http://www.ncbi.nlm.nih.gov/pubmed/22842478">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2433 href="https://doi.org/10.1038/nm.2883">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717954402">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d77711e2446 class=n-a></a>Kono K, Iinuma H, Akutsu Y, <i> et al.</i>: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. <i>J Transl Med.</i> 2012; <b>10</b>: 141. <a target=xrefwindow id=d77711e2457 href="http://www.ncbi.nlm.nih.gov/pubmed/22776426">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2460 href="https://doi.org/10.1186/1479-5876-10-141">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2464 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3403921">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d77711e2473 class=n-a></a>Hazama S, Nakamura Y, Takenouchi H, <i> et al.</i>: A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. <i>J Transl Med.</i> 2014; <b>12</b>: 63. <a target=xrefwindow id=d77711e2484 href="http://www.ncbi.nlm.nih.gov/pubmed/24612787">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2487 href="https://doi.org/10.1186/1479-5876-12-63">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2491 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4007571">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d77711e2501 class=n-a></a>Rini BI, Stenzl A, Zdrojowy R, <i> et al.</i>: IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(11): 1599–611. <a target=xrefwindow id=d77711e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/27720136">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2515 href="https://doi.org/10.1016/S1470-2045(16)30408-9">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726888446"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e2524 class=n-a></a>Suzuki N, Hazama S, Iguchi H, <i> et al.</i>: Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. <i>Cancer Sci.</i> 2017; <b>108</b>(1): 73–80. <a target=xrefwindow id=d77711e2535 href="http://www.ncbi.nlm.nih.gov/pubmed/27783849">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2538 href="https://doi.org/10.1111/cas.13113">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2542 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5276830">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726888446">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d77711e2555 class=n-a></a>Zom GG, Khan S, Britten CM, <i> et al.</i>: Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(8): 756–64. <a target=xrefwindow id=d77711e2566 href="http://www.ncbi.nlm.nih.gov/pubmed/24950688">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2569 href="https://doi.org/10.1158/2326-6066.CIR-13-0223">Publisher Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d77711e2578 class=n-a></a>Welters MJ, Kenter GG, Piersma SJ, <i> et al.</i>: Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. <i>Clin Cancer Res.</i> 2008; <b>14</b>(1): 178–87. <a target=xrefwindow id=d77711e2589 href="http://www.ncbi.nlm.nih.gov/pubmed/18172269">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2592 href="https://doi.org/10.1158/1078-0432.CCR-07-1880">Publisher Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d77711e2601 class=n-a></a>Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. <i>Nat Rev Cancer.</i> 2008; <b>8</b>(5): 351–60. <a target=xrefwindow id=d77711e2609 href="http://www.ncbi.nlm.nih.gov/pubmed/18418403">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2612 href="https://doi.org/10.1038/nrc2373">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d77711e2621 class=n-a></a>Kenter GG, Welters MJ, Valentijn AP, <i> et al.</i>: Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. <i>Clin Cancer Res.</i> 2008; <b>14</b>(5): 169–77. <a target=xrefwindow id=d77711e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/18172268">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2635 href="https://doi.org/10.1158/1078-0432.CCR-07-1881">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/720882163"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e2645 class=n-a></a>de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, <i> et al.</i>: A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. <i>Cancer Immunol Immunother.</i> 2012; <b>61</b>(9): 1485–92. <a target=xrefwindow id=d77711e2656 href="http://www.ncbi.nlm.nih.gov/pubmed/22684521">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2659 href="https://doi.org/10.1007/s00262-012-1292-7">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3427705">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/720882163">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d77711e2676 class=n-a></a>Leffers N, Lambeck AJ, Gooden MJ, <i> et al.</i>: Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. <i>Int J Cancer.</i> 2009; <b>125</b>(9): 2104–13. <a target=xrefwindow id=d77711e2687 href="http://www.ncbi.nlm.nih.gov/pubmed/19621448">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2690 href="https://doi.org/10.1002/ijc.24597">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d77711e2699 class=n-a></a>Sabbatini P, Tsuji T, Ferran L, <i> et al.</i>: Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. <i>Clin Cancer Res.</i> 2012; <b>18</b>(23): 6497–508. <a target=xrefwindow id=d77711e2710 href="http://www.ncbi.nlm.nih.gov/pubmed/23032745">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2713 href="https://doi.org/10.1158/1078-0432.CCR-12-2189">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d77711e2722 class=n-a></a>Zeestraten EC, Speetjens FM, Welters MJ, <i> et al.</i>: Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. <i>Int J Cancer.</i> 2013; <b>132</b>(7): 1581–91. <a target=xrefwindow id=d77711e2733 href="http://www.ncbi.nlm.nih.gov/pubmed/22948952">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2736 href="https://doi.org/10.1002/ijc.27819">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d77711e2745 class=n-a></a>Speetjens FM, Zeestraten EC, Kuppen PJ, <i> et al.</i>: Colorectal cancer vaccines in clinical trials. <i>Expert Rev Vaccines.</i> 2011; <b>10</b>(6): 899–921. <a target=xrefwindow id=d77711e2756 href="http://www.ncbi.nlm.nih.gov/pubmed/21692708">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2759 href="https://doi.org/10.1586/erv.11.63">Publisher Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d77711e2768 class=n-a></a>Muderspach L, Wilczynski S, Roman L, <i> et al.</i>: A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. <i>Clin Cancer Res.</i> 2000; <b>6</b>(9): 3406–16. <a target=xrefwindow id=d77711e2779 href="http://www.ncbi.nlm.nih.gov/pubmed/10999722">PubMed Abstract </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d77711e2789 class=n-a></a>Lee ST, Jiang YF, Park KU, <i> et al.</i>: BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. <i>Expert Opin Biol Ther.</i> 2007; <b>7</b>(1): 113–22. <a target=xrefwindow id=d77711e2800 href="http://www.ncbi.nlm.nih.gov/pubmed/17150023">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2803 href="https://doi.org/10.1517/14712598.7.1.113">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d77711e2812 class=n-a></a>Schuster SJ, Neelapu SS, Gause BL, <i> et al.</i>: Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. <i>J Clin Oncol.</i> 2011; <b>29</b>(20): 2787–94. <a target=xrefwindow id=d77711e2823 href="http://www.ncbi.nlm.nih.gov/pubmed/21632504">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2826 href="https://doi.org/10.1200/JCO.2010.33.3005">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2830 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3139394">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d77711e2839 class=n-a></a>Kloetzel PM, Ossendorp F: Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. <i>Curr Opin Immunol.</i> 2004; <b>16</b>(1): 76–81. <a target=xrefwindow id=d77711e2847 href="http://www.ncbi.nlm.nih.gov/pubmed/14734113">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2850 href="https://doi.org/10.1016/j.coi.2003.11.004">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d77711e2859 class=n-a></a>Rock KL, Reits E, Neefjes J: Present Yourself! By MHC Class I and MHC Class II Molecules. <i>Trends Immunol.</i> 2016; <b>37</b>(11): 724–37. <a target=xrefwindow id=d77711e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/27614798">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2870 href="https://doi.org/10.1016/j.it.2016.08.010">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2873 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5159193">Free Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d77711e2882 class=n-a></a>Frey BF, Jiang J, Sui Y, <i> et al.</i>: Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. <i>J Immunol.</i> 2018; <b>200</b>: 1853–64. <a target=xrefwindow id=d77711e2893 href="http://www.ncbi.nlm.nih.gov/pubmed/29374075">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2896 href="https://doi.org/10.4049/jimmunol.1701523">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5890335">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d77711e2909 class=n-a></a>Kumai T, Kobayashi H, Harabuchi Y, <i> et al.</i>: Peptide vaccines in cancer-old concept revisited. <i>Curr Opin Immunol.</i> 2017; <b>45</b>(5): 1–7. <a target=xrefwindow id=d77711e2920 href="http://www.ncbi.nlm.nih.gov/pubmed/27940327">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2923 href="https://doi.org/10.1016/j.coi.2016.11.001">Publisher Full Text </a> | <a target=xrefwindow id=d77711e2927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5449210">Free Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d77711e2937 class=n-a></a>Middleton G, Silcocks P, Cox T, <i> et al.</i>: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 829–40. <a target=xrefwindow id=d77711e2948 href="http://www.ncbi.nlm.nih.gov/pubmed/24954781">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2951 href="https://doi.org/10.1016/S1470-2045(14)70236-0">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d77711e2960 class=n-a></a>Butts C, Socinski MA, Mitchell PL, <i> et al.</i>: Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(1): 59–68. <a target=xrefwindow id=d77711e2971 href="http://www.ncbi.nlm.nih.gov/pubmed/24331154">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2974 href="https://doi.org/10.1016/S1470-2045(13)70510-2">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d77711e2983 class=n-a></a>Schuster J, Lai RK, Recht LD, <i> et al.</i>: A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. <i>Neuro Oncol.</i> 2015; <b>17</b>(6): 854–61. <a target=xrefwindow id=d77711e2994 href="http://www.ncbi.nlm.nih.gov/pubmed/25586468">PubMed Abstract </a> | <a target=xrefwindow id=d77711e2997 href="https://doi.org/10.1093/neuonc/nou348">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3001 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4483122">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d77711e3010 class=n-a></a>Coley WB: The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). <i>Proc R Soc Med.</i> 1910; <b>3</b>(Surg Sect): 1–48. <a target=xrefwindow id=d77711e3018 href="http://www.ncbi.nlm.nih.gov/pubmed/19974799">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3021 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1961042">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d77711e3030 class=n-a></a>Roberts NJ, Zhang L, Janku F, <i> et al.</i>: Intratumoral injection of <i>Clostridium novyi</i>-NT spores induces antitumor responses. <i>Sci Transl Med.</i> 2014; <b>6</b>(249): 249ra111. <a target=xrefwindow id=d77711e3044 href="http://www.ncbi.nlm.nih.gov/pubmed/25122639">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3048 href="https://doi.org/10.1126/scitranslmed.3008982">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3051 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4399712 ">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727738047"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3060 class=n-a></a>Kocijancic D, Felgner S, Schauer T, <i> et al.</i>: Local application of bacteria improves safety of <i>Salmonella</i> -mediated tumor therapy and retains advantages of systemic infection. <i>Oncotarget.</i> 2017; <b>8</b>(30): 49988–50001. <a target=xrefwindow id=d77711e3074 href="http://www.ncbi.nlm.nih.gov/pubmed/28637010">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3078 href="https://doi.org/10.18632/oncotarget.18392">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3081 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5564822">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727738047">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d77711e3095 class=n-a></a>Heap JT, Theys J, Ehsaan M, <i> et al.</i>: Spores of <i>Clostridium</i> engineered for clinical efficacy and safety cause regression and cure of tumors <i>in vivo.</i> <i>Oncotarget.</i> 2014; <b>5</b>(7): 1761–9. <a target=xrefwindow id=d77711e3113 href="http://www.ncbi.nlm.nih.gov/pubmed/24732092">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3116 href="https://doi.org/10.18632/oncotarget.1761">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4039107">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d77711e3128 class=n-a></a>Le DT, Brockstedt DG, Nir-Paz R, <i> et al.</i>: A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. <i>Clin Cancer Res.</i> 2012; <b>18</b>(3): 858–68. <a target=xrefwindow id=d77711e3139 href="http://www.ncbi.nlm.nih.gov/pubmed/22147941">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3142 href="https://doi.org/10.1158/1078-0432.CCR-11-2121">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3289408">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d77711e3155 class=n-a></a>Wall DM, Srikanth CV, McCormick BA: Targeting tumors with salmonella <i>Typhimurium</i>- potential for therapy. <i>Oncotarget.</i> 2010; <b>1</b>(8): 721–8. <a target=xrefwindow id=d77711e3166 href="http://www.ncbi.nlm.nih.gov/pubmed/21321381">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3169 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3157733">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d77711e3178 class=n-a></a>Lambin P, Theys J, Landuyt W, <i> et al.</i>: Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours. <i>Anaerobe.</i> 1998; <b>4</b>(4): 183–8. <a target=xrefwindow id=d77711e3189 href="http://www.ncbi.nlm.nih.gov/pubmed/16887640">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3192 href="https://doi.org/10.1006/anae.1998.0161">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d77711e3201 class=n-a></a>Hong EH, Chang SY, Lee BR, <i> et al.</i>: Intratumoral injection of attenuated <i>Salmonella</i> vaccine can induce tumor microenvironmental shift from immune suppressive to immunogenic. <i>Vaccine.</i> 2013; <b>31</b>(10): 1377–84. <a target=xrefwindow id=d77711e3215 href="http://www.ncbi.nlm.nih.gov/pubmed/23318147">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3219 href="https://doi.org/10.1016/j.vaccine.2013.01.006">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a name=d77711e3228 class=n-a></a>Lizotte PH, Baird JR, Stevens CA, <i> et al.</i>: Attenuated <i>Listeria monocytogenes</i> reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. <i>Oncoimmunology.</i> 2014; <b>3</b>(5): e28926. <a target=xrefwindow id=d77711e3242 href="http://www.ncbi.nlm.nih.gov/pubmed/25083323">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3246 href="https://doi.org/10.4161/onci.28926">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3249 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4106169">Free Full Text </a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d77711e3259 class=n-a></a>Bronchalo-Vicente L, Rodriguez-Del Rio E, Freire J, <i> et al.</i>: A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with <i>Listeria monocytogenes</i>. <i>PLoS One.</i> 2015; <b>10</b>(3): e0117923. <a target=xrefwindow id=d77711e3273 href="http://www.ncbi.nlm.nih.gov/pubmed/25760947">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3277 href="https://doi.org/10.1371/journal.pone.0117923">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3280 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4356589">Free Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d77711e3289 class=n-a></a>Vendrell A, Gravisaco MJ, Pasetti MF, <i> et al.</i>: A novel <i>Salmonella</i> Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. <i>Vaccine.</i> 2011; <b>29</b>(4): 728–36. <a target=xrefwindow id=d77711e3303 href="http://www.ncbi.nlm.nih.gov/pubmed/21095252">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3307 href="https://doi.org/10.1016/j.vaccine.2010.11.017">Publisher Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d77711e3316 class=n-a></a>Grille S, Moreno M, Bascuas T, <i> et al.</i>: <i>Salmonella enterica</i> serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. <i>Immunology.</i> 2014; <b>143</b>(3): 428–37. <a target=xrefwindow id=d77711e3330 href="http://www.ncbi.nlm.nih.gov/pubmed/24834964">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3334 href="https://doi.org/10.1111/imm.12320">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3337 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4212956">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d77711e3346 class=n-a></a>Sanders KL, Fox BA, Bzik DJ: Attenuated <i>Toxoplasma gondii</i> Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. <i>Cancer Immunol Res.</i> 2015; <b>3</b>(8): 891–901. <a target=xrefwindow id=d77711e3357 href="http://www.ncbi.nlm.nih.gov/pubmed/25804437">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3360 href="https://doi.org/10.1158/2326-6066.CIR-14-0235">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4526316">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d77711e3373 class=n-a></a>Maciag PC, Radulovic S, Rothman J: The first clinical use of a live-attenuated <i>Listeria monocytogenes</i> vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. <i>Vaccine.</i> 2009; <b>27</b>(30): 3975–83. <a target=xrefwindow id=d77711e3384 href="http://www.ncbi.nlm.nih.gov/pubmed/19389451">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3387 href="https://doi.org/10.1016/j.vaccine.2009.04.041">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d77711e3396 class=n-a></a>Wallecha A, Wood L, Pan ZK, <i> et al.</i>: <i>Listeria monocytogenes</i>-derived listeriolysin O has pathogen-associated molecular pattern-like properties independent of its hemolytic ability. <i>Clin Vaccine Immunol.</i> 2013; <b>20</b>(1): 77–84. <a target=xrefwindow id=d77711e3410 href="http://www.ncbi.nlm.nih.gov/pubmed/23136118">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3414 href="https://doi.org/10.1128/CVI.00488-12">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3417 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3535771">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d77711e3427 class=n-a></a>Chen Z, Ozbun L, Chong N, <i> et al.</i>: Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansions of CD4<sup>+</sup>FoxP3<sup>-</sup> and CD8<sup>+</sup> T cells. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(9): 911–22. <a target=xrefwindow id=d77711e3448 href="http://www.ncbi.nlm.nih.gov/pubmed/24872025">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3451 href="https://doi.org/10.1158/2326-6066.CIR-13-0197">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3454 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4160031">Free Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726033518"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3463 class=n-a></a>Lizotte PH, Wen AM, Sheen MR, <i> et al.</i>: <i>In situ</i> vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. <i>Nat Nanotechnol.</i> 2016; <b>11</b>(3): 295–303. <a target=xrefwindow id=d77711e3477 href="http://www.ncbi.nlm.nih.gov/pubmed/26689376">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3481 href="https://doi.org/10.1038/nnano.2015.292">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3484 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4777632">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726033518">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726267966"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3497 class=n-a></a>Rojas JJ, Sampath P, Bonilla B, <i> et al.</i>: Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. <i>Cell Rep.</i> 2016; <b>15</b>(2): 264–73. <a target=xrefwindow id=d77711e3508 href="http://www.ncbi.nlm.nih.gov/pubmed/27050526">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3511 href="https://doi.org/10.1016/j.celrep.2016.03.017">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3515 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4830920 ">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726267966">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1508956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3528 class=n-a></a>Lubaroff DM, Konety BR, Link B, <i> et al.</i>: Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. <i>Clin Cancer Res.</i> 2009; <b>15</b>(23): 7375–80. <a target=xrefwindow id=d77711e3539 href="http://www.ncbi.nlm.nih.gov/pubmed/19920098">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3542 href="https://doi.org/10.1158/1078-0432.CCR-09-1910">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3546 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2787649">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1508956">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d77711e3559 class=n-a></a>Yu Q, Hu N, Ostrowski M: Poxvirus tropism for primary human leukocytes and hematopoietic cells. <i>Methods Mol Biol.</i> 2009; <b>515</b>: 309–28. <a target=xrefwindow id=d77711e3567 href="http://www.ncbi.nlm.nih.gov/pubmed/19378122">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3570 href="https://doi.org/10.1007/978-1-59745-559-6_22">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d77711e3579 class=n-a></a>Harrop R, Shingler W, Kelleher M, <i> et al.</i>: Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. <i>J Immunother.</i> 2010; <b>33</b>(9): 999–1005. <a target=xrefwindow id=d77711e3590 href="http://www.ncbi.nlm.nih.gov/pubmed/20948436">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3593 href="https://doi.org/10.1097/CJI.0b013e3181f5dac7">Publisher Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d77711e3603 class=n-a></a>Tsang KY, Zaremba S, Nieroda CA, <i> et al.</i>: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. <i>J Natl Cancer Inst.</i> 1995; <b>87</b>(13): 982–90. <a target=xrefwindow id=d77711e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/7629885">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3617 href="https://doi.org/10.1093/jnci/87.13.982">Publisher Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d77711e3626 class=n-a></a>Hodge JW, Rad AN, Grosenbach DW, <i> et al.</i>: Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. <i>J Natl Cancer Inst.</i> 2000; <b>92</b>(15): 1228–39. <a target=xrefwindow id=d77711e3637 href="http://www.ncbi.nlm.nih.gov/pubmed/10922408">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3640 href="https://doi.org/10.1093/jnci/92.15.1228">Publisher Full Text </a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d77711e3649 class=n-a></a>Madan RA, Arlen PM, Gulley JL: PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma. <i>Expert Opin Biol Ther.</i> 2007; <b>7</b>(4): 543–54. <a target=xrefwindow id=d77711e3657 href="http://www.ncbi.nlm.nih.gov/pubmed/17373905">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3660 href="https://doi.org/10.1517/14712598.7.4.543">Publisher Full Text </a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d77711e3669 class=n-a></a>Grosenbach DW, Barrientos JC, Schlom J, <i> et al.</i>: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. <i>Cancer Res.</i> 2001; <b>61</b>(11): 4497–505. <a target=xrefwindow id=d77711e3680 href="http://www.ncbi.nlm.nih.gov/pubmed/11389081">PubMed Abstract </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d77711e3689 class=n-a></a>Gulley JL, Madan RA, Tsang KY, <i> et al.</i>: Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(2): 133–41. <a target=xrefwindow id=d77711e3700 href="http://www.ncbi.nlm.nih.gov/pubmed/24778277">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3703 href="https://doi.org/10.1158/2326-6066.CIR-13-0108">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3707 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4004961 ">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/735179665"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3716 class=n-a></a>Gulley JL, Borre M, Vogelzang NJ, <i> et al.</i>: Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. <i>J Clin Oncol.</i> 2019; <b>37</b>(13): 1051–1061. <a target=xrefwindow id=d77711e3727 href="http://www.ncbi.nlm.nih.gov/pubmed/30817251">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3730 href="https://doi.org/10.1200/JCO.18.02031">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/735179665">F1000 Recommendation</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d77711e3744 class=n-a></a>Kantoff PW, Schuetz TJ, Blumenstein BA, <i> et al.</i>: Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. <i>J Clin Oncol.</i> 2010; <b>28</b>(7): 1099–105. <a target=xrefwindow id=d77711e3755 href="http://www.ncbi.nlm.nih.gov/pubmed/20100959">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3758 href="https://doi.org/10.1200/JCO.2009.25.0597">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3762 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2834462">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d77711e3771 class=n-a></a>Dhodapkar MV, Steinman RM, Sapp M, <i> et al.</i>: Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. <i>J Clin Invest.</i> 1999; <b>104</b>(2): 173–80. <a target=xrefwindow id=d77711e3782 href="http://www.ncbi.nlm.nih.gov/pubmed/10411546">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3785 href="https://doi.org/10.1172/JCI6909">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3789 href="http://www.ncbi.nlm.nih.gov/pmc/articles/408478 ">Free Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d77711e3798 class=n-a></a>Banchereau J, Palucka AK: Dendritic cells as therapeutic vaccines against cancer. <i>Nat Rev Immunol.</i> 2005; <b>5</b>(4): 296–306. <a target=xrefwindow id=d77711e3806 href="http://www.ncbi.nlm.nih.gov/pubmed/15803149">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3809 href="https://doi.org/10.1038/nri1592">Publisher Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d77711e3818 class=n-a></a>Gabrilovich DI, Ciernik IF, Carbone DP: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. <i>Cell Immunol.</i> 1996; <b>170</b>(1): 101–10. <a target=xrefwindow id=d77711e3826 href="http://www.ncbi.nlm.nih.gov/pubmed/8665590">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3829 href="https://doi.org/10.1006/cimm.1996.0139">Publisher Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d77711e3838 class=n-a></a>Gabrilovich DI, Chen HL, Girgis KR, <i> et al.</i>: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. <i>Nat Med.</i> 1996; <b>2</b>(10): 1096–103. <a target=xrefwindow id=d77711e3849 href="http://www.ncbi.nlm.nih.gov/pubmed/8837607">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3852 href="https://doi.org/10.1038/nm1096-1096">Publisher Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d77711e3861 class=n-a></a>Bennaceur K, Chapman J, Brikci-Nigassa L, <i> et al.</i>: Dendritic cells dysfunction in tumour environment. <i>Cancer Lett.</i> 2008; <b>272</b>(2): 186–96. <a target=xrefwindow id=d77711e3872 href="http://www.ncbi.nlm.nih.gov/pubmed/18585853">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3875 href="https://doi.org/10.1016/j.canlet.2008.05.017">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725419742"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e3885 class=n-a></a>Carreno BM, Magrini V, Becker-Hapak M, <i> et al.</i>: Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. <i>Science.</i> 2015; <b>348</b>(6236): 803–8. <a target=xrefwindow id=d77711e3896 href="http://www.ncbi.nlm.nih.gov/pubmed/25837513">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3899 href="https://doi.org/10.1126/science.aaa3828">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3903 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4549796">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725419742">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d77711e3916 class=n-a></a>Castiello L, Sabatino M, Ren J, <i> et al.</i>: Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. <i>Clin Cancer Res.</i> 2017; <b>23</b>(13): 3352–64. <a target=xrefwindow id=d77711e3927 href="http://www.ncbi.nlm.nih.gov/pubmed/28073842">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3930 href="https://doi.org/10.1158/1078-0432.CCR-16-2199">Publisher Full Text </a> | <a target=xrefwindow id=d77711e3934 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5496805">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d77711e3943 class=n-a></a>Sakai Y, Morrison BJ, Burke JD, <i> et al.</i>: Vaccination by genetically modified dendritic cells expressing a truncated <i>neu</i> oncogene prevents development of breast cancer in transgenic mice. <i>Cancer Res.</i> 2004; <b>64</b>(21): 8022–8. <a target=xrefwindow id=d77711e3957 href="http://www.ncbi.nlm.nih.gov/pubmed/15520211">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3961 href="https://doi.org/10.1158/0008-5472.CAN-03-3442">Publisher Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d77711e3970 class=n-a></a>Schlitzer A, McGovern N, Ginhoux F: Dendritic cells and monocyte-derived cells: Two complementary and integrated functional systems. <i>Semin Cell Dev Biol.</i> 2015; <b>41</b>: 9–22. <a target=xrefwindow id=d77711e3978 href="http://www.ncbi.nlm.nih.gov/pubmed/25957517">PubMed Abstract </a> | <a target=xrefwindow id=d77711e3981 href="https://doi.org/10.1016/j.semcdb.2015.03.011">Publisher Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d77711e3990 class=n-a></a>Collin M, McGovern N, Haniffa M: Human dendritic cell subsets. <i>Immunology.</i> 2013; <b>140</b>(1): 22–30. <a target=xrefwindow id=d77711e3998 href="http://www.ncbi.nlm.nih.gov/pubmed/23621371">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4001 href="https://doi.org/10.1111/imm.12117">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3809702">Free Full Text </a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d77711e4013 class=n-a></a>Tel J, Aarntzen EH, Baba T, <i> et al.</i>: Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. <i>Cancer Res.</i> 2013; <b>73</b>(3): 1063–75. <a target=xrefwindow id=d77711e4024 href="http://www.ncbi.nlm.nih.gov/pubmed/23345163">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4027 href="https://doi.org/10.1158/0008-5472.CAN-12-2583">Publisher Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726542716"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4037 class=n-a></a>Roberts EW, Broz ML, Binnewies M, <i> et al.</i>: Critical Role for CD103<sup>+</sup>/CD141<sup>+</sup> Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. <i>Cancer Cell.</i> 2016; <b>30</b>(2): 324–36. <a target=xrefwindow id=d77711e4055 href="http://www.ncbi.nlm.nih.gov/pubmed/27424807">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4058 href="https://doi.org/10.1016/j.ccell.2016.06.003">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4061 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5374862">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726542716">F1000 Recommendation</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d77711e4074 class=n-a></a>Pulendran B, Banchereau J, Burkeholder S, <i> et al.</i>: Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets <i>in vivo</i>. <i>J Immunol.</i> 2000; <b>165</b>(1): 566–72. <a target=xrefwindow id=d77711e4088 href="http://www.ncbi.nlm.nih.gov/pubmed/10861097">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4092 href="https://doi.org/10.4049/jimmunol.165.1.566">Publisher Full Text </a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d77711e4101 class=n-a></a>Mohamadzadeh M, Berard F, Essert G, <i> et al.</i>: Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. <i>J Exp Med.</i> 2001; <b>194</b>(7): 1013–20. <a target=xrefwindow id=d77711e4112 href="http://www.ncbi.nlm.nih.gov/pubmed/11581322">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4115 href="https://doi.org/10.1084/jem.194.7.1013">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2193478">Free Full Text </a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d77711e4128 class=n-a></a>Da Silva DM, Woodham AW, Naylor PH, <i> et al.</i>: Immunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells. <i>J Interferon Cytokine Res.</i> 2016; <b>36</b>(5): 291–301. <a target=xrefwindow id=d77711e4139 href="http://www.ncbi.nlm.nih.gov/pubmed/26653678">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4142 href="https://doi.org/10.1089/jir.2015.0115">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4146 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4854212">Free Full Text </a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d77711e4155 class=n-a></a>Enamorado M, Iborra S, Priego E, <i> et al.</i>: Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8<sup>+</sup> T cells. <i>Nat Commun.</i> 2017; <b>8</b>: 16073. <a target=xrefwindow id=d77711e4169 href="http://www.ncbi.nlm.nih.gov/pubmed/28714465">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4173 href="https://doi.org/10.1038/ncomms16073">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4176 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5520051">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d77711e4185 class=n-a></a>Dhodapkar MV, Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8<sup>+</sup> regulatory T cells <i>in vivo</i> in humans. <i>Blood.</i> 2002; <b>100</b>(1): 174–7. <a target=xrefwindow id=d77711e4199 href="http://www.ncbi.nlm.nih.gov/pubmed/12070024">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4203 href="https://doi.org/10.1182/blood.V100.1.174">Publisher Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718357928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4213 class=n-a></a>Small EJ, Schellhammer PF, Higano CS, <i> et al.</i>: Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. <i>J Clin Oncol.</i> 2006; <b>24</b>(19): 3089–94. <a target=xrefwindow id=d77711e4224 href="http://www.ncbi.nlm.nih.gov/pubmed/16809734">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4227 href="https://doi.org/10.1200/JCO.2005.04.5252">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718357928">F1000 Recommendation</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d77711e4240 class=n-a></a>Kumar J, Kale V, Limaye L: Umbilical cord blood-derived CD11c<sup>+</sup> dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy. <i>Stem Cell Res Ther.</i> 2015; <b>6</b>: 184. <a target=xrefwindow id=d77711e4251 href="http://www.ncbi.nlm.nih.gov/pubmed/26407613">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4254 href="https://doi.org/10.1186/s13287-015-0160-8">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4258 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4583174">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d77711e4267 class=n-a></a>Gansuvd B, Hagihara M, Higuchi A, <i> et al.</i>: Umbilical cord blood dendritic cells are a rich source of soluble HLA-DR: synergistic effect of exosomes and dendritic cells on autologous or allogeneic T-Cell proliferation. <i>Hum Immunol.</i> 2003; <b>64</b>(4): 427–39. <a target=xrefwindow id=d77711e4278 href="http://www.ncbi.nlm.nih.gov/pubmed/12651069">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4281 href="https://doi.org/10.1016/S0198-8859(03)00016-8">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d77711e4290 class=n-a></a>Guo Y, Wu M, Chen H, <i> et al.</i>: Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. <i>Science.</i> 1994; <b>263</b>(5146): 518–20. <a target=xrefwindow id=d77711e4301 href="http://www.ncbi.nlm.nih.gov/pubmed/7507262">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4304 href="https://doi.org/10.1126/science.7507262">Publisher Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d77711e4313 class=n-a></a>Gong J, Chen D, Kashiwaba M, <i> et al.</i>: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. <i>Nat Med.</i> 1997; <b>3</b>(5): 558–61. <a target=xrefwindow id=d77711e4324 href="http://www.ncbi.nlm.nih.gov/pubmed/9142127">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4327 href="https://doi.org/10.1038/nm0597-558">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726044502"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4336 class=n-a></a>Schreibelt G, Bol KF, Westdorp H, <i> et al.</i>: Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clin Cancer Res.</i> 2016; <b>22</b>(9): 2155–66. <a target=xrefwindow id=d77711e4347 href="http://www.ncbi.nlm.nih.gov/pubmed/26712687">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4350 href="https://doi.org/10.1158/1078-0432.CCR-15-2205">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726044502">F1000 Recommendation</a></span></li><li><a name=ref-132 class=n-a></a><span class=label>132. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726185619"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4364 class=n-a></a>Garg AD, Vandenberk L, Koks C, <i> et al.</i>: Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma. <i>Sci Transl Med.</i> 2016; <b>8</b>(328): 328ra27. <a target=xrefwindow id=d77711e4375 href="http://www.ncbi.nlm.nih.gov/pubmed/26936504">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4378 href="https://doi.org/10.1126/scitranslmed.aae0105">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726185619">F1000 Recommendation</a></span></li><li><a name=ref-133 class=n-a></a><span class=label>133. </span>&nbsp;<span class=citation><a name=d77711e4391 class=n-a></a>Butterfield LH, Comin-Anduix B, Vujanovic L, <i> et al.</i>: Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. <i>J Immunother.</i> 2008; <b>31</b>(3): 294–309. <a target=xrefwindow id=d77711e4402 href="http://www.ncbi.nlm.nih.gov/pubmed/18317358">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4405 href="https://doi.org/10.1097/CJI.0b013e31816a8910">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4409 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3651040">Free Full Text </a></span></li><li><a name=ref-134 class=n-a></a><span class=label>134. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726183218"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4418 class=n-a></a>Wilgenhof S, Corthals J, Heirman C, <i> et al.</i>: Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(12): 1330–8. <a target=xrefwindow id=d77711e4429 href="http://www.ncbi.nlm.nih.gov/pubmed/26926680">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4432 href="https://doi.org/10.1200/JCO.2015.63.4121">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726183218">F1000 Recommendation</a></span></li><li><a name=ref-135 class=n-a></a><span class=label>135. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1000143"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4445 class=n-a></a>Su Z, Dannull J, Heiser A, <i> et al.</i>: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. <i>Cancer Res.</i> 2003; <b>63</b>(9): 2127–33. <a target=xrefwindow id=d77711e4456 href="http://www.ncbi.nlm.nih.gov/pubmed/12727829">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1000143">F1000 Recommendation</a></span></li><li><a name=ref-136 class=n-a></a><span class=label>136. </span>&nbsp;<span class=citation><a name=d77711e4469 class=n-a></a>Nair SK, Morse M, Boczkowski D, <i> et al.</i>: Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. <i>Ann Surg.</i> 2002; <b>235</b>(4): 540–9. <a target=xrefwindow id=d77711e4480 href="http://www.ncbi.nlm.nih.gov/pubmed/11923611">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4483 href="https://doi.org/10.1097/00000658-200204000-00013">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1422470">Free Full Text </a></span></li><li><a name=ref-137 class=n-a></a><span class=label>137. </span>&nbsp;<span class=citation><a name=d77711e4496 class=n-a></a>Sundarasetty BS, Chan L, Darling D, <i> et al.</i>: Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. <i>Gene Ther.</i> 2015; <b>22</b>(9): 707–20. <a target=xrefwindow id=d77711e4507 href="http://www.ncbi.nlm.nih.gov/pubmed/25965393">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4510 href="https://doi.org/10.1038/gt.2015.43">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4514 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4561294">Free Full Text </a></span></li><li><a name=ref-138 class=n-a></a><span class=label>138. </span>&nbsp;<span class=citation><a name=d77711e4524 class=n-a></a>Park JM, Terabe M, Steel JC, <i> et al.</i>: Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/<i>neu</i> vaccine. <i>Cancer Res.</i> 2008; <b>68</b>(6): 1979–87. <a target=xrefwindow id=d77711e4538 href="http://www.ncbi.nlm.nih.gov/pubmed/18339880">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4542 href="https://doi.org/10.1158/0008-5472.CAN-07-5688">Publisher Full Text </a></span></li><li><a name=ref-139 class=n-a></a><span class=label>139. </span>&nbsp;<span class=citation><a name=d77711e4551 class=n-a></a>Wood LV, Roberson BD, Agarwal PK, <i> et al.</i>: Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 3089. <a target=xrefwindow id=d77711e4562 href="https://doi.org/10.1200/JCO.2017.35.15_suppl.3089">Publisher Full Text </a></span></li><li><a name=ref-140 class=n-a></a><span class=label>140. </span>&nbsp;<span class=citation><a name=d77711e4571 class=n-a></a>Kolanowski ST, Sritharan L, Lissenberg-Thunnissen SN, <i> et al.</i>: Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy. <i>Cytotherapy.</i> 2014; <b>16</b>(6): 826–34. <a target=xrefwindow id=d77711e4582 href="http://www.ncbi.nlm.nih.gov/pubmed/24529557">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4585 href="https://doi.org/10.1016/j.jcyt.2013.12.005">Publisher Full Text </a></span></li><li><a name=ref-141 class=n-a></a><span class=label>141. </span>&nbsp;<span class=citation><a name=d77711e4594 class=n-a></a>Dohnal AM, Graffi S, Witt V, <i> et al.</i>: Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines. <i>J Cell Mol Med.</i> 2009; <b>13</b>(1): 125–35. <a target=xrefwindow id=d77711e4605 href="http://www.ncbi.nlm.nih.gov/pubmed/18363835">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4608 href="https://doi.org/10.1111/j.1582-4934.2008.00304.x">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4612 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3823041">Free Full Text </a></span></li><li><a name=ref-142 class=n-a></a><span class=label>142. </span>&nbsp;<span class=citation><a name=d77711e4621 class=n-a></a>Hatfield P, Merrick AE, West E, <i> et al.</i>: Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy. <i>J Immunother.</i> 2008; <b>31</b>(7): 620–32. <a target=xrefwindow id=d77711e4632 href="http://www.ncbi.nlm.nih.gov/pubmed/18600182">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4635 href="https://doi.org/10.1097/CJI.0b013e31818213df">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3901408">Free Full Text </a></span></li><li><a name=ref-143 class=n-a></a><span class=label>143. </span>&nbsp;<span class=citation><a name=d77711e4648 class=n-a></a>Lutz ER, Wu AA, Bigelow E, <i> et al.</i>: Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(7): 616–31. <a target=xrefwindow id=d77711e4659 href="http://www.ncbi.nlm.nih.gov/pubmed/24942756">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4662 href="https://doi.org/10.1158/2326-6066.CIR-14-0027">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4082460">Free Full Text </a></span></li><li><a name=ref-144 class=n-a></a><span class=label>144. </span>&nbsp;<span class=citation><a name=d77711e4676 class=n-a></a>García-Hernández ML, Uribe-Uribe NO, Espinosa-González R, <i> et al.</i>: A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. <i>Front Immunol.</i> 2017; <b>8</b>: 563. <a target=xrefwindow id=d77711e4687 href="http://www.ncbi.nlm.nih.gov/pubmed/28567040">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4690 href="https://doi.org/10.3389/fimmu.2017.00563">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5434117">Free Full Text </a></span></li><li><a name=ref-145 class=n-a></a><span class=label>145. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731922339"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4703 class=n-a></a>Le DT, Ko AH, Wainberg ZA, <i> et al.</i>: Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). <i>J Clin Oncol.</i> 2017; <b>35</b>(4_suppl): 345. <a target=xrefwindow id=d77711e4714 href="https://doi.org/10.1200/JCO.2017.35.4_suppl.345">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731922339">F1000 Recommendation</a></span></li><li><a name=ref-146 class=n-a></a><span class=label>146. </span>&nbsp;<span class=citation><a name=d77711e4727 class=n-a></a>Le DT, Wang-Gillam A, Picozzi V, <i> et al.</i>: Safety and survival with GVAX pancreas prime and <i>Listeria Monocytogenes</i>-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. <i>J Clin Oncol.</i> 2015; <b>33</b>(12): 1325–33. <a target=xrefwindow id=d77711e4741 href="http://www.ncbi.nlm.nih.gov/pubmed/25584002">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4745 href="https://doi.org/10.1200/JCO.2014.57.4244">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4748 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4397277">Free Full Text </a></span></li><li><a name=ref-147 class=n-a></a><span class=label>147. </span>&nbsp;<span class=citation><a name=d77711e4757 class=n-a></a>Iinuma T, Homma S, Noda T, <i> et al.</i>: Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. <i>J Clin Invest.</i> 2004; <b>113</b>(9): 1307–17. <a target=xrefwindow id=d77711e4768 href="http://www.ncbi.nlm.nih.gov/pubmed/15124022">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4771 href="https://doi.org/10.1172/JCI17323">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/398422">Free Full Text </a></span></li><li><a name=ref-148 class=n-a></a><span class=label>148. </span>&nbsp;<span class=citation><a name=d77711e4784 class=n-a></a>Saeterdal I, Bjørheim J, Lislerud K, <i> et al.</i>: Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(23): 13255–60. <a target=xrefwindow id=d77711e4795 href="http://www.ncbi.nlm.nih.gov/pubmed/11687624">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4798 href="https://doi.org/10.1073/pnas.231326898">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4802 href="http://www.ncbi.nlm.nih.gov/pmc/articles/60857">Free Full Text </a></span></li><li><a name=ref-149 class=n-a></a><span class=label>149. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730481855"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4811 class=n-a></a>Bol KF, Aarntzen EH, Pots JM, <i> et al.</i>: Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunol Immunother.</i> 2016; <b>65</b>(3): 327–39. <a target=xrefwindow id=d77711e4822 href="http://www.ncbi.nlm.nih.gov/pubmed/26861670">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4825 href="https://doi.org/10.1007/s00262-016-1796-7">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4779136">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730481855">F1000 Recommendation</a></span></li><li><a name=ref-150 class=n-a></a><span class=label>150. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732370179"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4843 class=n-a></a>Finn OJ: The dawn of vaccines for cancer prevention. <i>Nat Rev Immunol.</i> 2018; <b>18</b>(3): 183–94. <a target=xrefwindow id=d77711e4851 href="http://www.ncbi.nlm.nih.gov/pubmed/29279613">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4854 href="https://doi.org/10.1038/nri.2017.140">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732370179">F1000 Recommendation</a></span></li><li><a name=ref-151 class=n-a></a><span class=label>151. </span>&nbsp;<span class=citation><a name=d77711e4867 class=n-a></a>Gray A, Raff AB, Chiriva-Internati M, <i> et al.</i>: A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. <i>Immunol Rev.</i> 2008; <b>222</b>(1): 316–27. <a target=xrefwindow id=d77711e4878 href="http://www.ncbi.nlm.nih.gov/pubmed/18364011">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4881 href="https://doi.org/10.1111/j.1600-065X.2008.00605.x">Publisher Full Text </a></span></li><li><a name=ref-152 class=n-a></a><span class=label>152. </span>&nbsp;<span class=citation><a name=d77711e4890 class=n-a></a>Sharma A, Koldovsky U, Xu S, <i> et al.</i>: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma <i>in situ</i>. <i>Cancer.</i> 2012; <b>118</b>(17): 4354–62. <a target=xrefwindow id=d77711e4904 href="http://www.ncbi.nlm.nih.gov/pubmed/22252842">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4908 href="https://doi.org/10.1002/cncr.26734">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4911 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3330145">Free Full Text </a></span></li><li><a name=ref-153 class=n-a></a><span class=label>153. </span>&nbsp;<span class=citation><a name=d77711e4920 class=n-a></a>Finn OJ: Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. <i>Cancer Immunol Res.</i> 2014; <b>2</b>(8): 708–13. <a target=xrefwindow id=d77711e4928 href="http://www.ncbi.nlm.nih.gov/pubmed/25092812">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4931 href="https://doi.org/10.1158/2326-6066.CIR-14-0110">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4934 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4163937">Free Full Text </a></span></li><li><a name=ref-154 class=n-a></a><span class=label>154. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725387509"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d77711e4943 class=n-a></a>Mitchell DA, Batich KA, Gunn MD, <i> et al.</i>: Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. <i>Nature.</i> 2015; <b>519</b>(7543): 366–9. <a target=xrefwindow id=d77711e4954 href="http://www.ncbi.nlm.nih.gov/pubmed/25762141">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4957 href="https://doi.org/10.1038/nature14320">Publisher Full Text </a> | <a target=xrefwindow id=d77711e4961 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4510871">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725387509">F1000 Recommendation</a></span></li><li><a name=ref-155 class=n-a></a><span class=label>155. </span>&nbsp;<span class=citation><a name=d77711e4974 class=n-a></a>Fujiwara S, Wada H, Miyata H, <i> et al.</i>: Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. <i>J Immunother.</i> 2012; <b>35</b>(6): 513–21. <a target=xrefwindow id=d77711e4985 href="http://www.ncbi.nlm.nih.gov/pubmed/22735809">PubMed Abstract </a> | <a target=xrefwindow id=d77711e4988 href="https://doi.org/10.1097/CJI.0b013e3182619cb4">Publisher Full Text </a></span></li><li><a name=ref-156 class=n-a></a><span class=label>156. </span>&nbsp;<span class=citation><a name=d77711e4998 class=n-a></a>Verdijk P, Aarntzen EH, Lesterhuis WJ, <i> et al.</i>: Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. <i>Clin Cancer Res.</i> 2009; <b>15</b>(7): 2531–40. <a target=xrefwindow id=d77711e5009 href="http://www.ncbi.nlm.nih.gov/pubmed/19318472">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5012 href="https://doi.org/10.1158/1078-0432.CCR-08-2729">Publisher Full Text </a></span></li><li><a name=ref-157 class=n-a></a><span class=label>157. </span>&nbsp;<span class=citation><a name=d77711e5021 class=n-a></a>Lesterhuis WJ, de Vries IJ, Schreibelt G, <i> et al.</i>: Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. <i>Clin Cancer Res.</i> 2011; <b>17</b>(17): 5725–35. <a target=xrefwindow id=d77711e5032 href="http://www.ncbi.nlm.nih.gov/pubmed/21771874">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5035 href="https://doi.org/10.1158/1078-0432.CCR-11-1261">Publisher Full Text </a></span></li><li><a name=ref-158 class=n-a></a><span class=label>158. </span>&nbsp;<span class=citation><a name=d77711e5044 class=n-a></a>Fong L, Brockstedt D, Benike C, <i> et al.</i>: Dendritic cells injected via different routes induce immunity in cancer patients. <i>J Immunol.</i> 2001; <b>166</b>(6): 4254–9. <a target=xrefwindow id=d77711e5055 href="http://www.ncbi.nlm.nih.gov/pubmed/11238679">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5058 href="https://doi.org/10.4049/jimmunol.166.6.4254">Publisher Full Text </a></span></li><li><a name=ref-159 class=n-a></a><span class=label>159. </span>&nbsp;<span class=citation><a name=d77711e5067 class=n-a></a>Djenidi F, Adam J, Goubar A, <i> et al.</i>: CD8<sup>+</sup>CD103<sup>+</sup> tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. <i>J Immunol.</i> 2015; <b>194</b>(7): 3475–86. <a target=xrefwindow id=d77711e5085 href="http://www.ncbi.nlm.nih.gov/pubmed/25725111">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5088 href="https://doi.org/10.4049/jimmunol.1402711">Publisher Full Text </a></span></li><li><a name=ref-160 class=n-a></a><span class=label>160. </span>&nbsp;<span class=citation><a name=d77711e5097 class=n-a></a>Ganesan AP, Clarke J, Wood O, <i> et al.</i>: Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. <i>Nat Immunol.</i> 2017; <b>18</b>(8): 940–50. <a target=xrefwindow id=d77711e5108 href="http://www.ncbi.nlm.nih.gov/pubmed/28628092">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5111 href="https://doi.org/10.1038/ni.3775">Publisher Full Text </a> | <a target=xrefwindow id=d77711e5115 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6036910">Free Full Text </a></span></li><li><a name=ref-161 class=n-a></a><span class=label>161. </span>&nbsp;<span class=citation><a name=d77711e5124 class=n-a></a>Cheever MA, Schlom J, Weiner LM, <i> et al.</i>: Translational Research Working Group developmental pathway for immune response modifiers. <i>Clin Cancer Res.</i> 2008; <b>14</b>(18): 5692–9. <a target=xrefwindow id=d77711e5135 href="http://www.ncbi.nlm.nih.gov/pubmed/18794077">PubMed Abstract </a> | <a target=xrefwindow id=d77711e5138 href="https://doi.org/10.1158/1078-0432.CCR-08-1266">Publisher Full Text </a> | <a target=xrefwindow id=d77711e5142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6383515">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 May 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-654/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-654/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA<br/> <p> <div class=margin-bottom> Hoyoung M. Maeng <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Jay A. Berzofsky <br/> <span>Roles: </span> Conceptualization, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-654/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 13 May 2019, 8:654 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.18693.1">https://doi.org/10.12688/f1000research.18693.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Maeng HM and Berzofsky JA. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=20468 data-id=18693 data-downloads="" data-views="" data-scholar="10.12688/f1000research.18693.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-654/v1/pdf?article_uuid=524009f8-be9a-431f-bad9-2a142f31ff5e" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.18693.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Maeng HM and Berzofsky JA. Strategies for developing and optimizing cancer vaccines [version 1; peer review: 2 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):654 (<a href="https://doi.org/10.12688/f1000research.18693.1" target=_blank>https://doi.org/10.12688/f1000research.18693.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=18693 id=mobile-track-article-signin-18693 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/18693?target=/articles/8-654/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=20468 /> <input name=articleId type=hidden value=18693 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Madhav Dhodapkar</strong>, Winship Cancer Institute, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>W. Martin Kast</strong>, Departments of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, University of Southern California, Norris Comprehensive Cancer Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 13 May 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-654/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-654/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=50347-47956></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=50349-47957></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-654/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>13 May 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Madhav Dhodapkar</strong>, Winship Cancer Institute, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>W. Martin Kast</strong>, Departments of Molecular Microbiology & Immunology, Obstetrics & Gynecology and Urology, University of Southern California, Norris Comprehensive Cancer Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-654/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-654/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Strategies for developing and optimizing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-654/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-654/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-654/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Maeng HM and Berzofsky JA');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-654/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-654",
            templates : {
                twitter : "Strategies for developing and optimizing cancer vaccines. Maeng HM and Berzofsky JA, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-654/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Strategies for developing and optimizing cancer vaccines", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Strategies for developing and optimizing cancer vaccines", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/18693/20468")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "20468");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "47956": 0,
                           "47957": 3,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "efe01007-273c-488f-9591-ed5963e2bd9a";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-654.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-654.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-654.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-654.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-654.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>